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Genetic and Chemical Modifiers of EGFR Dependence in Non-Small Cell Lung Cancer 
 
ABSTRACT 
 
 The term ‘oncogene addiction’ has been used to describe the phenomenon whereby 
tumor cells exhibit singular reliance on an oncogene or oncogenic pathway for their survival, 
despite the accumulation of multiple genetic lesions. In non-small cell lung cancer (NSCLC), this 
principle is perhaps best exemplified with the finding that epidermal growth factor receptor 
(EGFR) mutations predict response to EGFR-targeted therapies and thus represent a 
dependency in the subset of tumors harboring these alterations. Yet while EGFR-mutant tumors 
often respond dramatically to EGFR inhibition, nearly 30% of cases are refractory to therapy at 
the outset, and all responsive patients ultimately develop resistance to therapy. A deeper 
understanding of the genetic underpinnings of EGFR dependence, and of the mechanisms by 
which EGFR-mutant cells can overcome addiction to EGFR, may improve clinical outcomes. 
 In this work, we have applied systematic functional screening approaches to identify 
modifiers of EGFR dependence in NSCLC. Recent advances in large-scale functional screening 
libraries have made it possible to query a wide-range of genetic or chemical perturbations for 
their ability to modulate specific cellular phenotypes. Using the model of EGFR-mutant, erlotinib-
sensitive NSCLC cells, we have performed systematic open reading frame (ORF)- and shRNA-
based screens to identify genetic perturbations that can complement loss of EGFR in an EGFR-
dependent context. Additionally, by integrating screening findings with an unbiased, gene-
expression-based approach, we have identified chemical compounds that can modulate the 
degree to which cells rely on EGFR. Our findings indicate broad potential for EGFR substitution 
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in the setting of EGFR dependence, with compensatory mechanisms commonly conferring 
EGFR-independent activation of the phosphoinositide 3-kinase (PI3K)-AKT and MEK-ERK 
signaling pathways. These data support the idea that the EGFR-addicted state can be 
redundantly driven by diverse genetic inputs that commonly converge on shared downstream 
signaling nodes. 
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Summary 
 Lung cancer is a wide-ranging term that encompasses several heterogeneous 
malignancies of the lung. While lung cancer was once treated as a single disease entity, the 
observation that lung tumors of distinct subtypes could display differential response to therapy 
has precipitated a refined classification of this disease and its treatment. It is now understood 
that specific genetic alterations can drive the growth and survival of these tumors, and in turn, 
render them highly susceptible to specific targeted therapies. In this manner, mutations in the 
epidermal growth factor receptor (EGFR) drive a subset of non-small cell lung cancers 
(NSCLCs) and predict responsiveness to EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and 
erlotinib. Indeed, EGFR-mutant NSCLCs exemplify the phenomenon of ‘oncogene addiction’ in 
their singular reliance on EGFR for activation of critical downstream signaling pathways and 
exquisite sensitivity to EGFR inhibition.  
 Yet while EGFR-mutant NSCLCs often respond dramatically to EGFR inhibitors, the 
development of resistance to EGFR-TKIs following an initial response (acquired resistance), or 
the failure to respond to begin with (primary resistance), confound clinical benefit. Several 
mechanisms of primary and acquired resistance to EGFR-TKIs have been identified, and these 
can be broadly categorized as either intrinsic or extrinsic to EGFR. In the latter case, primary 
and acquired resistance to therapy can be attributed to the existence of key genetic modifiers 
that can regulate the degree to which these tumors rely on EGFR. A deeper understanding of 
which genes or pathways are able to reduce dependency on EGFR, as well as which genes or 
pathways are required to maintain the oncogene-addicted state, may reveal new therapeutic 
opportunities in these cancers and will be the subject of this work. 
 
Lung cancer classification and treatment paradigms   
Overview 
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 Lung cancer is the leading cause of death from cancer in the Unites States and across 
the world, estimated to cause over 160,000 deaths in the U.S. annually [1] and over 1.3 million 
deaths per year worldwide [2]. Cancers of the lung have been estimated to account for 28% of 
all cancer-related deaths in the United States in 2012, despite representing only 14% of new 
cancer diagnoses. Further illustrating the lethality of this disease, the 5-year survival rate for 
patients diagnosed with lung cancer is only 16%, considerably lower than the survival rates for 
cancers of the breast, colon, and prostate [1].  
 The high mortality rate of lung cancer is attributable to several factors, including the high 
incidence of the disease and the typically advanced stage at diagnosis: approximately two-thirds 
of patients present with locally advanced or metastatic disease [3]. Moreover, until recently, this 
clinically, histologically, and molecularly heterogeneous disease was treated as a single 
malignancy, with treatment based predominantly on clinical stage [4]. The recognition that lung 
cancer could be sub-stratified based on histological and molecular criteria, and that lung tumors 
of distinct subtypes could display differential response to therapy, has extended overall survival 
and improved response rates of patients with advanced disease [5,6,7]. Continued refinement of 
the distinct disease subsets represented within this cancer type holds promise in revealing new 
therapeutic opportunities or improving patient selection methods for specific therapies. 
Histological classification of lung cancer 
 Lung cancer is a wide-ranging term that encompasses several heterogeneous 
malignancies of the lung, but can be broadly classified into small-cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC), the latter of which accounts for approximately 87% of lung 
cancer cases [8]. These two types of lung cancer are usually distinguished according to clinical, 
histological, and neuroendocrine features [9,10]. NSCLC can be further divided by histological 
criteria into three major subtypes: adenocarcinoma, squamous cell carcinoma, or large-cell 
carcinoma [9]. 
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 Adenocarcinomas are the most common subtype of NSCLC, accounting for 41% of all 
NSCLC cases [11]. These tumors typically arise peripherally, and can be further subdivided 
based on histological criteria into acinar, papillary, broncholoalveolar, solid adenocarcinoma 
with mucin formation, or mixed subtypes [12]. 
Conventional treatments for non-small cell lung cancer  
 Treatment for NSCLC varies by tumor type and stage, and may include surgery, 
radiation therapy, chemotherapy, or a combination of modalities. Surgical resection is the 
standard approach for patients with stage I and II NSCLC [13], while stage III cancers are often 
treated with combined chemoradiotherapy, with or without surgery [14]. For stage IV patients, 
palliation of symptoms and prolongation of survival are primary goals, and treatment may 
consist of chemotherapy, palliative radiotherapy, or targeted therapy [15,16,17].  
 For patients with advanced NSCLC, cytotoxic chemotherapy regimens commonly 
consist of treatment with a platinum-based doublet (e.g. carboplatin plus paclitaxel) [16]. A 
randomized clinical trial comparing four platinum-based doublet regimens (cisplatin-paclitaxel, 
cisplatin-gemcitabine, cisplatin-docetaxel, carboplatin-paclitaxel) reported median survival 
values of 7-8 months under each of the four regimens [18]. It has been reported that the 
addition of a third agent, the vascular endothelial growth factor (VEGF)-directed monoclonal 
antibody bevacizumab, can provide an overall survival benefit in non-squamous-cell NSCLC 
patients treated with carboplatin and paclitaxel, extending the median overall survival of patients 
to 12.3 months as compared to 10.3 months in the chemotherapy-alone group [19].  
 More recently, a phase III study has demonstrated that use of the antifolate pemetrexed 
in combination with cisplatin is superior to cisplatin plus gemcitabine in NSCLC patients with 
adenocarcinoma and large-cell carcinoma histology [5]. Intriguingly, pemetrexed-cisplatin 
treatment was predictive of poor outcome in patients with squamous cell histology in this study 
[5]. The observation that histology can be a predictive marker of treatment response has been 
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reported with other chemotherapy regimens in advanced NSCLC [6], and is now understood to 
be a critical component in treatment selection [16]. 
Oncogene addiction and targeted therapies 
 In recent years, further sub-classification of lung cancer based on molecular criteria has 
been precipitated by the understanding that specific genetic alterations can drive and maintain 
tumor growth, and that tumors harboring different driver mutations may display differential 
sensitivity to targeted therapies. The term ‘oncogene addiction’ has been used to describe the 
phenomenon whereby tumor cells exhibit singular reliance on an oncogene or oncogenic 
pathway for their survival, despite the accumulation of multiple genetic lesions [20] (Figure I-1). 
While the mechanisms underlying oncogene addiction are not fully understood, this principle 
provides a basis for pharmacologically targeting the required oncogene in these tumor cells and 
thereby achieving cancer-cell selectivity [21]. Indeed, oncogene addiction appears to underlie 
the observed clinical responses to BCR-ABL inhibition in chronic myeloid leukemias (CML) 
harboring BCR-ABL translocations [22]; HER2-targeted therapy in HER2-positive breast 
cancers [23]; KIT inhibition in KIT-positive gastrointestinal stromal tumors (GIST) [24], and 
mutant-BRAF inhibition in BRAF-mutant melanoma [25], among other examples. In lung cancer, 
the most extensively-studied example of oncogene addiction is that of EGFR dependence in 
EGFR-mutant NSCLC [26,27,28,29]. More recently, ALK rearrangements have been 
demonstrated to represent another tumor dependency mechanism in NSCLC [30]. 
Molecular classification of lung cancer 
 Alongside these findings, genome characterization efforts over the last several years 
have dramatically refined our understanding of the genetic changes that drive and maintain lung 
tumorigenesis. Since 1987, when recurrent driver mutations in KRAS were first identified in 
NSCLC [31], this disease has been increasingly subdivided on the basis of specific molecular  
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Figure I-1. The phenomenon of oncogene addiction. Cancers arise through a multistage 
process, in which a normal cell develops into a benign tumor, then a primary cancer, and 
ultimately an invasive metastasis (and possibly other subpopulation[s]), through the progressive 
accumulation of genetic mutations. These mutations can lead to the activation of oncogenes or 
the inactivation of tumor suppressor genes [32,33]. In oncogene-addicted cancers, tumors 
exhibit dependence not on the totality of these mutations, but rather on a single mutant protein 
(red arrow) for their growth and survival [20,21]. Inactivation of such a driver oncogene (red 
cross) can achieve tumor cell death and thus represents a therapeutic opportunity in these 
cancers. Figure adapted from [33]. 
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criteria [7]. Examples of driver alterations identified in NSCLC within approximately the last 
decade include the aforementioned EGFR mutations [34,35,36] and EML4-ALK fusions [37], as 
well as HER2 (ERBB2) mutations [38,39,40], BRAF mutations [41,42,43], PIK3CA mutations 
[44,45], AKT1 mutations [46], MEK1 mutations [47], NRAS mutations [48,49], and translocations 
involving ROS1 [50,51,52,53] or RET [53,54,55,56]. Recently, a study of 183 lung 
adenocarcinomas has also identified recurrent somatic mutations in the splicing factor gene 
U2AF1 and truncating mutations in RBM10 and ARID1A [57], though the functional 
consequence of these mutations has not yet been determined. In addition to mutations and 
translocations, copy number gains are also typical in lung adenocarcinomas, frequently 
occurring in TERT, MYC, EGFR, and NKX2-1 [57,58]. 
 Lung adenocarcinomas can also be annotated on the basis of loss-of-function mutations 
and deletions, though at present these alterations are less likely to be therapeutically tractable. 
Mutations in the TP53 tumor suppressor, for example, are highly prevalent in lung 
adenocarcinoma, occurring at a frequency of approximately 50% [48,57,59]. Other tumor 
suppressor genes with loss-of-function mutations in lung adenocarcinoma include STK11, RB1, 
NF1, ATM, CDKN2A, SMARCA4, and KEAP1 [48,57,60,61,62]. Copy number deletions are 
commonly observed in TP53 and CDKN2A, among other genes [57,58]. 
 Importantly, a large percentage of lung adenocarcinomas do not harbor a known 
oncogenic driver alteration [63], indicating that our understanding of the genetic underpinnings 
of lung adenocarcinoma is likely incomplete. It is possible that larger patient cohorts may be 
required to assign significance to low-frequency alterations [57], or that there exist driver 
alterations generated by mechanisms undetectable by current genome characterization 
methods. 
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EGFR oncogene addiction in non-small cell lung cancer 
 Perhaps the most well-studied driver alteration in NSCLC is mutation of the epidermal 
growth factor receptor (EGFR) gene. Activating kinase domain mutations in EGFR are present 
in 10-15% of Caucasian and 30-40% of Asian NSCLC patients erlotinib [34,35,36,64,65], and 
these alterations strongly correlate with clinical response to the EGFR-tyrosine kinase inhibitors 
gefitinib and erlotinib [26,27,28,29].  
The ErbB family of receptor tyrosine kinases  
 EGFR (also known as ERBB1/HER1) belongs to the ErbB family of receptor tyrosine 
kinases, of which ERBB2/HER2, ERBB3/HER3, and ERBB4/HER4 are also members. Each of 
these ErbB receptors is structurally comprised of an extracellular ligand-binding domain, a 
single-pass transmembrane domain, and a cytoplasmic tyrosine kinase domain. Activation of 
these receptors, which under normal conditions are inactive and monomeric, can be mediated 
by binding of their ligands, members of the EGF-family of ligands, to the extracellular region of 
the receptor (reviewed in [66,67]). It is worth noting that ERBB3 lacks intrinsic kinase activity 
[68], and a soluble ligand for ERBB2 has not been identified [69]. Upon ligand-binding, these 
receptors undergo conformational changes that promote homo- and heterodimerization, leading 
to intrinsic kinase domain activation and autophosphorylation of key tyrosine residues in the 
carboxy-terminus. These phosphorylated tyrosine residues can then serve as docking sites for 
proteins containing Src homology 2 (SH2) or phosphotyrosine-binding (PTB) domains, leading 
to the activation of intracellular signaling pathways [66,67,70].  
EGFR signaling and oncogene addiction 
 As described above, activating mutations in EGFR have been reported in a large subset 
of NSCLC patients cases [34,35,36,63,64], and the presence of these mutations predicts 
sensitivity to the EGFR-TKIs gefitinib and erlotinib [26,27,28,29]. In NSCLC, activating 
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mutations occur in exons 18-21 of EGFR, residing within the tyrosine kinase domain of the 
receptor [71]. The two most common types of EGFR activating mutations, together accounting 
for over 90% of cases, are an in-frame deletion in exon 19 (commonly deleting amino-acid 
residues 746-750), and a leucine-to-arginine substitution in exon 21 (L858R), though several 
other kinase domain mutations have been associated with inhibitor sensitivity, including 
substitutions of the glycine residue at position 719 [27,29,71]. 
 On a structural level, it is thought that EGFR mutations alter the catalytic activity of 
EGFR by destabilizing the inactive conformation of the kinase [72]. Indeed, the crystal structure 
of the L858R EGFR mutant reveals a conformation very similar to the wild-type kinase in the 
activated conformation, but it appears that the substitution of a bulkier, charged arginine residue 
for leucine renders this mutation incompatible with the kinase’s inactive conformation [72]. 
Locking the kinase in a constitutively active state is thought to explain the approximately 50-fold 
increase in catalytic activity observed for the mutant versus wild-type kinase [72]. Compared to 
the wild-type kinase, mutant EGFR can confer ligand-independent activation of EGFR and is 
transforming in both in vitro and in vivo systems [73,74]. 
 EGFR exerts pro-survival and pro-proliferative effects predominantly via signaling 
through the phosphoinositide 3-kinase (PI3K)-AKT and RAS-RAF-MEK-ERK pathways, though 
Src kinase, PLCγ-PKC, and STAT signal transduction pathways are also known to be targets of 
activation [70,75]. In EGFR-mutant tumors, downstream signaling pathways are under the 
singular regulation of EGFR, rendering these cells dependent or ‘addicted’ to EGFR for their 
growth and survival [76,77]. When EGFR is inhibited in these mutant cells, critical downstream 
pathways, including those of AKT, STAT, and ERK, are suppressed and cells undergo 
apoptosis [76,77,78,79]. EGFR-TKI-mediated cell death in EGFR-mutant cells is induced the 
intrinsic, or mitochondrial, apoptotic pathway and depends on the pro-apoptotic BCL2 family 
member BIM, which is regulated by ERK signaling [80,81,82].  
10 
 
 Despite these advances, the mechanisms underlying EGFR oncogene addiction are at 
present not fully understood. One model that has been proposed to explain the phenomenon of 
oncogene addiction, termed ‘oncogenic shock’, suggests that differential signal attenuation 
between more transient pro-survival signals and more lagging pro-apoptotic signals following 
oncogene inactivation permits a crucial time window for apoptosis in these cells [71,83]. 
Importantly, the expression of EGFR mutations in transfected cells is not sufficient to render 
cells dependent on EGFR signaling for survival [71], underscoring the role of cellular context in 
supporting the EGFR-addicted state. 
 
Resistance to EGFR-targeted therapies 
 Despite the sometimes dramatic clinical responses of EGFR-mutant tumors to gefitinib 
or erlotinib, clinical responses are not universal, with the rate of objective response estimated to 
be approximately 71% [26,29]. Moreover, even patients who initially respond to EGFR inhibitors 
almost invariably acquire resistance to therapy [84]. The development of resistance to EGFR-
TKIs following an initial response (acquired resistance), or the failure to respond to begin with 
(primary resistance), continue to be significant clinical problems and are active areas of 
research. 
Primary resistance 
 Several mechanisms are known to mediate primary resistance to EGFR-TKIs, and these 
mechanisms can be either intrinsic or extrinsic to EGFR. Specific types of EGFR kinase domain 
mutations, such as in-frame duplication and/or insertion mutations in exon 20 of EGFR, are 
associated with reduced sensitivity to EGFR-TKIs [74,85]. It has been demonstrated that 
insertion mutations in exon 20, for example, can induce oncogenic transformation but require 
100-fold higher concentrations of erlotinib to inhibit this phenotype than required for the L858R 
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or exon 19 deletion mutants [74]. Moreover, the T790M mutation in exon 20 (described below), 
though typically associated with acquired resistance, has been reported in drug-naïve patients 
with co-occurring sensitizing EGFR mutations [86,87] and corresponds to reduced progression-
free survival in these patients following EGFR-TKI therapy [87]. 
 Primary resistance to therapy may also be influenced by genetic factors extrinsic to 
EGFR. It has been suggested that activation of the insulin-like growth factor 1 receptor (IGF-1R) 
signaling pathway, for example, may contribute to the emergence of EGFR-TKI-tolerant cells in 
an otherwise drug-sensitive population [88]. Co-treatment of EGFR-mutant cells with an EGFR-
TKI and an IGF-1R inhibitor is sufficient to prevent the development of these drug-tolerant cells 
[88]. Loss of phosphatase and tensin homolog (PTEN) has also been described as a 
mechanism underlying reduced sensitivity of EGFR-mutant cells to EGFR-TKIs [89], possibly 
through impaired PTEN-mediated ubiquitylation and degradation of EGFR [90]. Seemingly 
contradictory to these findings, a large study conducted in NSCLC patients treated with gefitinib 
did not find expression levels of IGF-1R or loss of PTEN to be associated with primary 
resistance to therapy [91], though this study was performed in an unselected patient population 
and thus may not reflect response rates when controlling for EGFR mutation status. More 
recently, it has been observed that lower BIM expression in treatment-naïve patients with 
EGFR-mutant lung cancers predicts worse progression-free survival following EGFR-TKI 
treatment [92]. Thus BIM expression may play a role in the observed heterogeneity of treatment 
response in EGFR-mutant lung cancers [92]. 
Acquired resistance 
Secondary mutations in EGFR 
 As previously mentioned, among patients who initially respond to EGFR-TKIs, the 
development of acquired resistance to therapy is universal, with a median time to progression of 
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approximately 12 months [93]. In approximately 50% of acquired resistance cases, EGFR-TKI 
insensitivity can be attributed to the development of a secondary kinase domain mutation in 
EGFR itself, leading to the substitution of a methionine for a threonine at position 790 (T790M) 
[93,94,95,96]. Also termed the ‘gatekeeper’ mutation, T790M is analogous to resistance-
associated mutations in BCR-ABL (T315I), PDGFRA (T6741), and KIT (T6701) following 
imatinib treatment [95,97,98,99]. While it was initially surmised that T790M sterically hinders 
drug binding, as occurs with T315I mutations in BCR-ABL, it now appears that the mutation 
reduces drug sensitivity by increasing the receptor’s affinity for its natural substrate ATP 
[97,100]. Other studies have also shown that the presence of T790M in cis with a canonical 
activating mutation enhances the kinase activity and transforming potential of EGFR relative to 
either mutation alone [73]. 
 Because EGFR-mutant tumors harboring the T790M mutation still depend on EGFR, the 
use of second- and third-generation EGFR inhibitors that retain activity against T790M have 
been pursued in these cancers. Second-generation, irreversible, quinazoline-based EGFR 
inhibitors afatinib and dacomitinib, for example, are effective in overcoming T790M-mediated 
resistance in preclinical models, presumably due to their covalent binding and thus greater ATP-
binding site occupancy [100,101,102]. Third-generation, irreversible, pyrimidine-based EGFR 
inhibitors, such as WZ4002, have also been developed to increase potency and selectivity for 
T790M-positive EGFR [103]. Clinical trials assessing whether the efficacy of several irreversible 
EGFR inhibitors translates in patients are ongoing [104]. 
 Other secondary EGFR mutations, such as D761Y, L747S, and T854A, have also been 
associated with acquired EGFR-TKI resistance, although these mutations occur very rarely in 
patients [105,106,107]. These secondary EGFR mutations also appear to reduce drug 
sensitivity much more modestly than T790M in in vitro assays [105,108,109]. 
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Bypass mechanisms 
 Another common route by which EGFR-mutant tumors acquire resistance to EGFR-TKIs 
is through so-called ‘bypass’ mechanisms, in which activation of an alternative signaling effector 
can sustain signaling activation downstream of EGFR in an EGFR-independent fashion. The 
most well-studied bypass mechanism in EGFR-mutant NSCLC is amplification of the receptor 
tyrosine kinase MET, which accounts for approximately 20% of acquired resistance cases 
[110,111]. MET amplification is able to mediate resistance, in spite of EGFR inhibition, through 
persistent activation of PI3K in an ERBB3-dependent manner [110]. Elevated expression of the 
ligand for MET, hepatocyte growth factor or HGF, has also been identified as a mechanism of 
EGFR-TKI resistance [112]. Importantly, combined EGFR and MET inhibition can overcome 
MET-mediated EGFR-TKI resistance in vitro and in vivo [110,113]. 
 More recent studies have implicated several additional bypass mechanisms in EGFR-
inhibitor resistance. Mutations in PIK3CA have recently been reported in a small fraction (5%) of 
tumors with acquired resistance to EGFR-TKIs [93], providing clinical evidence for earlier in vitro 
studies demonstrating oncogenic mutant PIK3CA to be sufficient to confer resistance to gefitinib 
through sustained activation of PI3K signaling [114]. Another recent study reported increased 
expression of the receptor tyrosine kinase AXL in in vitro and in vivo EGFR-mutant lung cancer 
models with acquired resistance to erlotinib [115]. Clinical specimens resistant to EGFR-TKIs 
were found to harbor increased expression of AXL (20% of evaluable cases) and/or its ligand 
GAS6 (25% of evaluable cases), with or without a co-occurring T790M mutation [115]. 
Furthermore, yet another potential bypass mechanism is amplification of the ErbB family 
member HER2 (ERBB2), which has been observed in 12-13% of EGFR-mutant patient tumors 
with acquired resistance to EGFR-TKIs and can occur independently of the T790M secondary 
mutation [116,117]. Supporting the notion that these alterations could be causative in driving 
resistance, HER2 overexpression is sufficient to induce resistance to erlotinib in an in vitro 
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context [116]. In vitro studies have also implicated overexpression of CRKL, which encodes an 
adaptor protein and is frequently amplified in NSCLC, as sufficient to induce resistance to 
gefitinib [118]. CRKL mediates gefitinib resistance through persistent MAPK and AKT signaling 
[118]. 
 Bypass mechanisms have also been implicated in acquired resistance to newer, 
irreversible EGFR inhibitors. Ercan et al. have recently identified amplification of mitogen-
activated protein kinase 1 (MAPK1) as a resistance mechanism to the third-generation EGFR 
inhibitor WZ4002 in models harboring EGFR-T790M [119]. Interestingly, in contrast to earlier 
work that had identified preferential amplification of the EGFR-T790M allele in EGFR-T790M-
containing models with acquired resistance to dacomitinib [120], the findings with WZ4002 
suggest that bypass mechanisms can occur secondarily to gatekeeper mutations in EGFR 
[119]. 
 Collectively, these findings suggest that activation of alternative signaling proteins may 
represent a more general way in which cancers overcome dependence on a primary driver 
oncogene.  
 Related to this phenomenon of EGFR bypass, recent work has implicated FAS and 
members of the nuclear factor (NF)-κB pathway as genetic modifiers of EGFR dependence in 
EGFR-mutant cells [121]. Bivona and colleagues have demonstrated that EGFR dependence is 
enhanced by downregulation of the FAS-NF-κB pathway, NF-κB activation confers EGFR-TKI 
resistance, and that high levels of NF-κB activation (as measured by low expression of the NF-
κB inhibitor IκB) predict worse progression-free and overall survival in EGFR-mutant NSCLC 
patients treated with an EGFR-TKI [121]. 
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Histological transformation 
 Intriguingly, a recent study has reported histological changes in EGFR-mutant NSCLC 
tumors after the development of acquired resistance to EGFR-TKIs, potentially identifying a new 
class of resistance mechanism in this disease [93]. In analyzing pre-treatment and post-relapse 
NSCLC tumor specimens, Sequist et al. noted that some resistant cancers lacking known 
resistance mechanisms displayed morphological changes consistent with an epithelial-to-
mesenchymal transition, which is associated with disease aggressiveness. Related to this 
notion of histological transformation, these authors also reported a surprising finding that 5 of 37 
(14%) drug-resistant tumor biopsies had a diagnosis of SCLC at the time of TKI resistance, 
suggesting a histological transformation from NSCLC to SCLC during the course of TKI 
treatment. These SCLC specimens retained their original EGFR mutation and were in some 
cases responsive to SCLC chemotherapy [93]. These findings are consistent with other 
observations reporting EGFR-mutant, SCLC diagnoses after progression on EGFR-TKI therapy 
[122,123]. It is at present unclear if these histological changes reflect bona fide transformation 
from NSCLC to SCLC, or rather selection for pre-existing SCLC clones following EGFR-TKI 
treatment. 
 
Context for the current work and thesis summary 
 EGFR mutations represent a clinically-relevant Achilles’ heel in the subset of non-small 
cell lung cancers harboring these alterations. Typically, these tumors are singularly reliant on 
EGFR for their proliferation and survival and are thus responsive to EGFR-targeted therapies. 
Yet the phenomenon of EGFR oncogene addiction itself implies a unique cellular circuitry that 
may be exploited alongside EGFR. Moreover, primary and acquired resistance to therapy 
suggests the existence of key genetic modifiers that in some cases can regulate the degree to 
which these tumors rely on EGFR. The question of which genes or pathways are able to reduce 
16 
 
dependency on EGFR, as well as which genes or pathways are required to maintain the 
oncogene-addicted state— questions bearing important implications for the development of 
long-term therapeutic strategies and overcoming acquired drug resistance—will be the subject 
of this work.  
 In these studies, we have sought to identify modifiers of EGFR dependence in NSCLC 
by applying systematic functional screening approaches. The advent of large-scale functional 
screening libraries has made it possible to query a wide-range of genetic or chemical 
perturbagens for their ability to modulate specific cellular phenotypes. In Chapter 1, we describe 
an open reading frame (ORF)-based genetic complementation screen for loss of EGFR in an 
EGFR-dependent model. Our findings indicate broad potential for kinase substitution in the 
setting of EGFR dependence and nominate two genes that may modify EGFR dependence in 
the clinical setting. In Chapter 2, we integrate these screening findings with an unbiased, gene-
expression-based connectivity approach to identify commonalities and differences among these 
EGFR bypass genes. We find that many EGFR bypass genes have shared transcriptional 
effects, commonly re-activate the PI3K-AKT and MEK-ERK pathways under EGFR inhibition, 
and can regain dependence on EGFR via PI3K-mTOR and MEK co-inhibition. Using this gene-
expression-based approach, we also identify chemical compounds that can reduce dependence 
on EGFR. In Chapter 3, we describe a genome-scale shRNA-based screen to identify genes 
required for EGFR dependence. We identify numerous candidate genes for further investigation 
and present intersecting findings between loss- and gain-of-function approaches. Together, 
these studies aim to identify genetic and chemical modifiers of EGFR dependence as a means 
to gain insight into the molecular underpinnings of EGFR oncogene addiction. 
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CHAPTER 1 
 
Diverse Kinase Genes Can Induce EGFR-Inhibitor Resistance 
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This chapter is reprinted from a manuscript in preparation. 
All experiments and analyses were performed by Tanaz Sharifnia except as follows: 
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Bagul. Analyses represented in Figures 1-5A were performed and visualized by Andrew Cherniack and 
Marcin Imielinski. Analyses represented in Figures 1-5B, 1-6, and Table 1-2 were performed by Andrew 
Cherniack and Tanaz Sharifnia. 
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ABSTRACT 
 Epidermal growth factor receptor (EGFR) activating mutations in non-small cell lung 
cancer (NSCLC) can predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs), but clinical 
benefit is limited by primary and acquired resistance. Activation of alternative driver kinases is a 
common route by which EGFR-mutant cancers develop resistance to EGFR-TKIs, but the full-
range of kinases capable of mediating EGFR bypass has not been systematically studied. Using 
an open reading frame (ORF)-based screen, we identified 18 kinase and kinase-related genes 
whose expression promotes resistance to the EGFR-TKI erlotinib in EGFR-mutant lung cancer 
cells. Resistance-inducing genes identified include seven of nine Src-family kinases, FGFR1, 
FGFR2, ITK, NTRK1, NTRK2, MOS, MST1R, and RAF1. Pharmacological blockade of 
resistance-promoting kinases restores sensitivity to erlotinib. Genomic profiling of lung 
adenocarcinomas reveals significantly co-occurring alterations in EGFR and resistance-inducing 
genes FGR and LCK, suggesting a role for these genes in modifying dependence on EGFR in 
the clinical setting. These data uncover a broad spectrum of kinases capable of circumventing 
EGFR inhibition in the setting of EGFR dependence.  
 
INTRODUCTION 
 Lung adenocarcinomas harboring activating mutations in the epidermal growth factor 
receptor (EGFR) represent a common molecular subset of non-small cell lung cancer cases 
[1,2,3,4,5], and the presence of these alterations strongly correlates with clinical response to the 
EGFR tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib [6,7,8,9].Yet while most EGFR 
mutation-positive NSCLC patients experience marked tumor regression upon treatment with a 
TKI, clinical responses are not universal even within this genetically-defined cohort, with the rate 
of objective response estimated to be approximately 71% [6,9]. Furthermore, the overwhelming 
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majority of patients who initially respond to EGFR inhibitors ultimately acquire resistance to 
therapy [10]. 
 In many instances, EGFR-TKI resistance can be attributed to the development of a 
secondary mutation in EGFR itself (T790M, or the ‘gatekeeper’ mutation), which occurs in 
approximately 50% of acquired resistance cases and reduces drug sensitivity by increasing the 
receptor’s affinity for its natural substrate ATP [11,12,13,14]. In other cases, primary or acquired 
refractoriness to therapy may stem from the activity of key genetic modifiers that can reduce 
these cancers’ dependence on EGFR [15]. Examples include amplification of the MET receptor 
tyrosine kinase (RTK) [16,17] or activation of MET via its ligand, hepatocyte growth factor or 
HGF [18], activation of the nuclear factor (NF)-κB pathway [15], amplification of the HER2 
(ERBB2) RTK [19], amplification of the CRKL gene [20], and activation of the AXL kinase [21]. 
Notably, and consistent with these findings, MET bypass can be reciprocally achieved via EGFR 
activation in MET-dependent cells [22], and analogous examples of reciprocal kinase switching 
have been reported in other kinase-driven cancer models [23,24]. These and other findings 
suggest that compensatory kinase switching may be a more general way in which oncogene-
dependent cancers overcome reliance on their primary driver kinase [23,25]. 
 Importantly, there remain many cases of primary and acquired EGFR-TKI resistance in 
which the underlying mechanism(s) are not understood [14,26]. We hypothesized that 
knowledge of the spectrum of kinases capable of mediating EGFR-inhibitor resistance could 
potentially identify novel mechanisms of resistance as well as elucidate shared features of 
kinase-driven EGFR bypass.  
 Discovery and characterization of known EGFR-TKI resistance mechanisms have been 
enabled by various experimental approaches to studying drug resistance, including the creation 
of isogenic drug-sensitive and resistant cell line pairs via stepwise selection methods, in vivo 
studies using genetically engineered mouse models, and direct profiling of pre-treatment and 
post-relapse human tumor samples [10,27]. Identification of new RTK bypass genes has been 
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facilitated by the advent of large-scale functional screening libraries, which make it possible to 
query a wide-range of genetic events sufficient to drive resistance to a given therapeutic agent 
[28,29]. This study has applied an unbiased, systematic cDNA screening approach to identify 
the range of kinase and kinase-related genes that, when highly expressed, are able to 
circumvent EGFR inhibition and promote drug resistance in EGFR-mutant cells. This approach 
has simultaneously enabled the recovery of previously characterized, clinically-validated 
mechanisms of erlotinib resistance as well as the identification of novel mediators of EGFR 
bypass in EGFR-mutant NSCLC. 
 
RESULTS 
An ORF-based screen identifies 18 kinase and kinase-related genes whose expression is 
sufficient to confer resistance to EGFR inhibition 
 To identify genes that rescue EGFR tyrosine kinase inhibition in the setting of EGFR 
dependence, we performed an open reading frame (ORF) overexpression screen in an EGFR-
dependent NSCLC cell line in the presence of erlotinib. A library of 589 open reading frames 
(ORFs) encoding human kinases and kinase-related proteins (Center for Cancer Systems 
Biology (CCSB)/Broad Institute Kinase ORF Collection) [28,29] was expressed via lentiviral 
transduction in the EGFR-mutant NSCLC cell line, PC9, which is sensitive to EGFR-TKIs with a 
half-maximal inhibitory concentration (IC50) of approximately 30 nM [30]. ORF-expressing PC9 
cells were treated with either 300 nM erlotinib, 3 µM erlotinib, or DMSO for 72h before being 
assayed for cell viability. Experimental ORFs were screened alongside positive control EGFR 
ORFs, encoding the T790M gatekeeper mutation in cis with a canonical EGFR activating 
mutation (EGFR-Δ(E746-A750)-T790M and EGFR-L858R-T790M) [31], as well as ORFs 
encoding activating alleles of several mitogen-activated protein kinase (MAPK) family members. 
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 Cell viability under screening conditions was very low; the median relative viability for all 
experimental ORFs was 12% at the 300 nM dose and 8% at the 3 µM dose (Figure 1-1). 
Overexpression of nineteen ORFs, of the 589 tested, led to a significant increase in viability of 
erlotinib-treated PC9 cells, with viability of at least 39% in 300 nM erlotinib and at least 31% in 3 
µM erlotinib (Figure 1-1). The genes whose ectopic expression led to greater viability in the 
presence of erlotinib include genes previously implicated in driving EGFR-inhibitor resistance 
(AXL, ERBB2, CRKL) as well as genes and gene families that are newly identified candidate 
drivers of EGFR-inhibitor resistance in EGFR-mutant lung cancer cells, including eight of the 
nine Src-family kinase members, as well as FGFR1 and FGFR2, ITK, NTRK1 and NTRK2, 
MOS, MST1R, and RAF1. The 19 genes whose expression led to apparent erlotinib resistance 
in the primary screen were selected for validation and functional characterization.  
 cDNA vectors corresponding to the 19 candidate resistance genes were sequence-
verified and confirmed to express protein by immunoblot (Figure 1-2A). PC9 cells ectopically 
expressing each of these ORFs were assayed for their sensitivity to erlotinib across multiple 
drug doses using 72h growth inhibition assays (Figure 1-2B). For comparison, the erlotinib-
resistant EGFR-mutant positive controls EGFR-Δ(E746-A750)-T790M (henceforth referred to as 
EGFR-ex19del-T790M) and EGFR-L858R-T790M were tested in parallel. Ectopic expression of 
18 of the 19 candidate resistance ORFs was capable of reducing sensitivity to erlotinib relative 
to cells transduced with an inert ORF (Figure 1-2B). This reduction in erlotinib sensitivity 
corresponded to a >2-fold to >400-fold shift in IC50 values (Table 1-1). One primary screening 
hit, YES1, failed to confer erlotinib resistance in our validation studies, leaving seven of nine 
Src-family kinase genes confirmed to confer the resistance phenotype (Figure 1-2B and Table 
1-1); and notably, among ORFs selected for validation, this gene scored nearest to the cutoff we 
used to select hits (Figure 1-1). 
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Figure 1-1. An ORF-based screen identifies 18 kinase and kinase-related genes sufficient 
to mediate resistance to EGFR inhibition. Screening results for PC9 cells transduced with a 
library of kinase ORFs, treated with 300 nM or 3 μM erlotinib or vehicle, then assayed for cell 
viability after 72h using CellTiter-Glo. Experimental ORFs (green points) were screened 
alongside EGFR-ex19del-T790M and EGFR-L858R-T790M positive controls (yellow points); 
activating alleles of the MAPK family (orange points); inert gene controls (red points); and no 
virus controls (blue points). Data are expressed as percent viability relative to vehicle. Nineteen 
candidate drivers of erlotinib resistance were selected for validation.  
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Figure 1-2. Validation of screening data. (A) Protein expression of ectopically-expressed 
ORFs. Immunoblot analysis of PC9 cells overexpressing candidate resistance-mediating ORFs 
and controls following treatment with DMSO for 6h. Cells were incubated with 0.5% serum 
media 18h before and during DMSO treatment. Total cell lysates were immunoblotted for 
ectopic protein expression using a V5-directed antibody. (B) PC9 cells expressing candidate 
resistance-inducing ORFs (green curve), EGFR-ex19del-T790M and EGFR-L858R-T790M 
positive controls (red and orange curves, respectively), and inert gene controls (light and dark 
blue curves) were treated with increasing concentrations of erlotinib and assayed for cell 
viability after 72h using CellTiter-Glo. Data are expressed as percent viability relative to vehicle- 
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Figure 1-2 (Continued)  
treated cells and represent the mean ± SD of 4 replicates. Graphs with identical control curves 
reflect experiments performed in parallel on the same day. 
 
 
 
Table 1-1. IC50 values of ORF-screen validation experiments. Absolute IC50 values 
corresponding to validation experiments described in Figure 1-2B.  
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Pharmacological blockade of resistance-promoting kinases restores sensitivity to 
erlotinib, and combination treatment is associated with downregulation of phospho-AKT 
 As both the screening set and the candidate erlotinib-resistance genes were enriched for 
human kinase genes, we sought to determine whether the observed resistance phenotypes 
were kinase-dependent, as well as to verify the specificity of the ORF-induced phenotype, by 
testing whether enzymatic inhibition of resistance-promoting kinases could restore sensitivity to 
erlotinib. To this end, PC9 cells transduced with kinase ORFs were treated with erlotinib alone, 
the relevant resistance-kinase inhibitor (where available) alone, or their combination for 72h, 
then assayed for cell viability with CellTiter-Glo (Figure 1-3 and Figure 1-4A). Inhibitors tested 
included dasatinib (targeting the Src-family kinases); XL880 (targeting AXL and MST1R); NVP-
BGJ398 (hereafter referred to as BGJ398) (targeting FGFR1 and FGFR2); lestaurtinib (targeting 
NTRK1 and NTRK2); lapatinib (targeting ERBB2); and AZ628 (targeting RAF1). 
 We observed that cells expressing Src-family kinase genes could indeed be rendered 
sensitive to erlotinib when treated in combination with the Src-family kinase inhibitor dasatinib, 
whereas these cells were not similarly sensitive to either agent alone (Figure 1-3A and Figure 1-
4A). In contrast, enhanced drug sensitivity under combined erlotinib/dasatinib treatment was not 
achieved in cells expressing EGFR-ex19del-T790M. Gene-specific rescue of erlotinib sensitivity 
was similarly observed for AXL, MST1R, FGFR1 and FGFR2, NTRK1 and NTRK2, ERBB2, and 
RAF1 upon co-treatment with their respective inhibitors (Figure 1-3B-F and Figure 1-
4A).Together, these data suggest that the resistant phenotype conferred by these ORFs is 
indeed specific to the encoded gene and requires the kinase activity of the expressed protein. 
36 
 
 
Figure 1-3. Pharmacological blockade of resistance-promoting kinases restores 
sensitivity to erlotinib. Cell viability of PC9 cells overexpressing indicated resistance-inducing 
kinases and controls following treatment with increasing concentrations of erlotinib (purple  
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Figure 1-3 (Continued)  
curve), the relevant kinase inhibitor (light blue curve), or their combination (orange curve) for 
72h. Cell viability was assayed with CellTiter-Glo. Data are expressed as percent viability 
relative to vehicle-treated cells and represent the mean ± SD of ≥ 3 replicates. These dose-
response curves were used to generate area under curve (AUC) values, plotted in Figure 1-4A. 
Kinase inhibitors tested included (A) dasatinib for Src-family kinases; (B) XL880 for AXL and 
MST1R; (C) BGJ398 for FGFR-family kinases; (D) lestaurtinib for NTKR-family kinases; (E) 
lapatinib for ERBB2; and (F) AZ628 for RAF1. Graphs with identical control curves reflect 
experiments performed in parallel on the same day. 
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Figure 1-4. Pharmacological blockade of resistance-promoting kinases restores erlotinib 
sensitivity, and combination drug treatment is associated with downregulation of 
phospho-AKT.  (A) Inhibitor sensitivity of PC9 cells expressing indicated resistance-inducing 
kinases and controls following treatment with multiple doses of erlotinib, the relevant kinase  
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Figure 1-4 (Continued) 
inhibitor, or their combination for 72h. Cell viability was assayed with CellTiter-Glo, and the 
resultant dose-response curves (Figure 1-3) were used to generate area under curve (AUC) 
values, plotted. Darker/lighter squares represent smaller/larger AUC values. (B-G) Immunoblot 
analysis of PC9 cells expressing resistance-inducing kinases and controls under combination 
drug treatment. Transduced cells were treated with indicated doses of erlotinib, the relevant 
kinase inhibitor, or a combination for 6h. Cells were incubated with 0.5% serum media 18h 
before and during drug/DMSO treatment. Total cell lysates were immunoblotted for the indicated 
proteins. Kinase inhibitors tested included (B) dasatinib for Src-family kinases; (C) XL880 for 
AXL and MST1R; (D) BGJ398 for FGFR-family kinases; (E) lestaurtinib for NTKR-family 
kinases; (F) lapatinib for ERBB2; and (G) AZ628 for RAF1.  
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 A few kinase inhibitors showed somewhat different patterns of growth-inhibition or 
rescue. We noted that lestaurtinib alone possesses some activity in LACZ- and EGFR-ex19del-
T790M-transduced cells (Figure 1-3D and Figure 1-4A), though only NTRK1- and NTRK2-
expressing cells exhibit enhanced sensitivity under combination treatment. We also observed 
that re-sensitization to erlotinib occurs only modestly in the case of RAF1-transduced cells 
treated with AZ628 (Figure 1-3F and Figure 1-4A), a finding that is consistent with previous work 
identifying overexpression of RAF1 itself as a mechanism of resistance to RAF inhibition [29].  
 Next, since EGFR-TKI treatment in EGFR-mutant cells typically elicits downregulation of 
the phosphoinositide 3-kinase (PI3K)-AKT and MEK-ERK signaling pathways [2], we sought to 
determine whether the observed rescue of drug sensitivity using combination treatment versus 
monotherapy was associated with a distinct PI3K-AKT and/or MEK-ERK signaling profile. ORF-
expressing cells were treated with erlotinib, the relevant kinase inhibitor, or their combination for 
6h, and assayed by immunoblotting for activation of downstream signaling proteins (Figure 1-
4B-G). As displayed in Figure 1-4B, LACZ-expressing cells undergo the expected 
downregulation of phospho-EGFR, phospho-AKT, and phospho-ERK1/2 in the presence of 
erlotinib, in contrast to EGFR-ex19del-T790M-expressing cells. We observed that cells 
transduced with Src-family kinases, however, maintain AKT phosphorylation in the presence of 
100 nM erlotinib, and this effect is reversed only upon co-treatment with dasatinib. Selective 
loss of AKT phosphorylation under combination-treatment was similarly observed in cells 
transduced with ERBB2, NTRK1 and NTRK2, and to a lesser extent with FGFR1 and FGFR2, 
AXL, and MST1R (Figure 1-4C-F). Together these data suggest that AKT activation is 
associated with resistance in these cells, and raise the possibility that ORF-driven resistance 
may be mediated by the PI3K-AKT pathway. Further inquiry into these findings will be discussed 
in Chapter 2. 
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 We did not observe selective abrogation of phospho-AKT levels in RAF1-expressing 
cells co-treated with erlotinib and AZ628 (Figure 1-4G), though as previously mentioned, this 
combination was also not sufficient to fully sensitize these cells (Figure 1-3F). We also noted 
that combined erlotinib/AZ628 treatment does not abolish phospho-ERK activation in these cells 
(Figure 1-4G), potentially explaining RAF1’s partial re-sensitization phenotype. Incidentally, 
treatment with AZ628 in LACZ- and EGFR-ex19del-T790M-expressing cells, but not RAF1-
expressing cells, paradoxically induces activation of ERK (Figure 1-4G), a finding that has 
previously been observed with RAF inhibitors in other RAFWT models [32,33]. 
 
Lung adenocarcinomas harboring LCK and FGR copy number gain are significantly more 
likely to possess concomitant EGFR mutations and amplifications 
 To evaluate whether in vitro erlotinib-resistance genes are altered in primary human 
tumors, we next queried somatic mutation and copy number alteration data from 230 lung 
adenocarcinoma cases, profiled as part of The Cancer Genome Atlas (TCGA), for the presence 
of alterations in genes identified in our ORF screen (Broad Institute TCGA Firehose, [34]). We 
hypothesized that alterations in these genes, if co-occurring with EGFR mutations, could drive 
de novo TKI resistance in patients with such tumors or represent pre-existing mechanisms of 
acquired resistance. In order to help distinguish tumors with bona fide EGFR dependency from 
those harboring ‘passenger’ mutations in EGFR, we defined ‘EGFR activating mutations’ to 
include only those known or predicted to have an activating function (see Table 1-2, and 
Materials and Methods).  
 In comparing alterations in EGFR and our panel of resistance-promoting genes, we 
noticed a pattern of co-occurrence between alterations in EGFR and copy number gain of two 
resistance-inducing genes, FGR and LCK (Figure 1-5A, top panel), which reside less than 5 Mb  
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Table 1-2. EGFR mutations present in lung adenocarcinoma primary tumors and 
classification by predicted function. Non-silent somatic EGFR mutations present in (A) 
TCGA cohort of 230 patients and (B) validation cohort of 182 patients. Mutations were classified 
as ‘activating’ or ‘non-activating missense’ using criteria described in Materials and Methods. 
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Figure 1-5. Lung adenocarcinomas harboring copy number gain in FGR and LCK are 
significantly more likely to possess concomitant EGFR mutations or amplifications. (A) 
Somatic copy number alterations and mutations in EGFR and resistance-promoting genes FGR 
and LCK across a cohort of 230 TCGA primary lung adenocarcinomas (top panel) and across a 
validation cohort of 182 primary lung adenocarcinomas (bottom panel). Each patient tumor is 
represented by a column. (B) Left panel: TCGA primary lung adenocarcinoma tumors harboring 
FGR and LCK amplifications possess EGFR activating mutations or EGFR amplifications at a 
significantly higher frequency than patients lacking copy number gain of FGR and LCK. Right 
panel: A validation cohort of 182 lung adenocarcinoma cases similarly reveals a significant 
enrichment for EGFR activating mutations or amplifications in tumors harboring copy number 
gain of FGR and LCK. P-values were calculated using a one-tailed Fisher’s exact test.  
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apart on chromosome 1p and are frequently co-amplified in this sample set. Indeed, we found 
that patients harboring copy number gain in FGR and LCK were significantly more likely to have 
EGFR activating mutations (odds ratio [OR] = 8.8; 95% confidence interval [CI], 3.5 – 21.7; P < 
0.0001), EGFR gene amplifications (OR = 5.5; 95% CI, 2.3 – 13.1; P < 0.0001) or either one or 
both alterations (OR = 7.5; 95% CI, 2.9 – 19.3; P < 0.0001) (Figure 1-6A; Figure 1-5B, left).  
 To validate these findings, we similarly surveyed somatic mutation and copy number 
alteration data from an independent sample set [35] of 182 lung adenocarcinoma patients for 
alterations in EGFR and resistance-promoting genes. As with the TCGA cohort, we observed 
significant enrichment of EGFR alterations in patients harboring FGR and LCK copy number 
gain (OR = 13.4; 95% CI, 1.7 – 108.5; P = 0.0024) (Figure 1-5A, bottom panel; Figure 1-5B, 
right). Consistent with the TCGA cohort, this enrichment remains significant when considering 
EGFR activating mutations and EGFR gene amplifications independently (OR = 36.5; 95% CI, 
7.2 – 185.9; P < 0.0001) and (OR = 6.9; 95% CI, 1.4 – 33.6; P = 0.0086), respectively (Figure 1-
6B). Collectively, these findings provide strong evidence for a non-random relationship between 
alterations in FGR/LCK and EGFR dependency in lung adenocarcinoma, and raise the 
possibility that alterations in these genes could modify EGFR dependence in the clinical setting. 
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Figure 1-6. Lung adenocarcinoma patients harboring copy number gain of FGR and LCK 
have a significantly higher frequency of co-occurring EGFR activating mutations and a 
significantly higher frequency of co-occurring EGFR amplifications. (A) TCGA lung 
adenocarcinoma patients with copy number gain of FGR and LCK are significantly more likely to 
harbor EGFR activating mutations (left panel) and significantly more likely to harbor EGFR 
amplifications (right panel) than patients lacking amplification of FGR and LCK. A similar pattern 
can be observed in (B) a validation cohort of 182 lung adenocarcinoma cases. P-values were 
calculated using a one-tailed Fisher’s exact test.   
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DISCUSSION 
 We report the use of a systematic ORF-based screening approach to identify the 
spectrum of human kinases capable of bypassing reliance on EGFR in EGFR-mutant lung 
cancer cells. To our knowledge, this represents the first instance of a cDNA-based genetic 
complementation screen for loss of EGFR in an EGFR-mutant model. This ORF-based 
screening approach has simultaneously recovered known, clinically-validated mechanisms of 
erlotinib resistance as well as identified novel mediators of EGFR bypass in EGFR-mutant 
NSCLC. More generally, it has revealed the breadth and diversity of kinase and kinase-related 
genes capable of replacing EGFR in the setting of EGFR oncogene-addiction: 18 genes 
reported herein, including several tyrosine kinase subfamilies of both receptor and non-receptor 
kinase classes, as well as serine/threonine kinases.  
 Identifying the spectrum of kinases capable of EGFR bypass is of considerable clinical 
interest given that patients with EGFR-mutant NSCLCs almost invariably acquire resistance to 
EGFR-directed therapy [10]; a large fraction (30%) of acquired resistance cases are driven by 
unknown mechanism(s) [14]; and because mounting evidence suggests that activation of 
alternative driver kinases, such as MET, represents a more general route by which kinase-
driven cancers acquire resistance to therapy [16,17,21,29]. Importantly, in the case of MET 
activation in EGFR-mutant cells, combined EGFR and MET inhibition effectively overcomes 
MET-mediated EGFR-TKI resistance in vitro and in vivo [16,36]. These findings suggest that 
elucidating novel mechanisms of EGFR bypass could in principle inform the development of 
rational combination therapies to delay or treat the development of acquired resistance. 
 As previously mentioned, the known and clinically-validated drivers of erlotinib 
resistance recovered by our screen include the RTK gene AXL, the ErbB-family member 
ERBB2 (HER2), and the gene encoding the adaptor protein CRKL [19,20,21]. Additionally, this 
ORF-based strategy has enabled the discovery of several novel drivers of EGFR bypass in 
EGFR-mutant NSCLC. Among these, we were struck by the high representation of Src-family 
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kinases, constituting greater than one-third of screening hits and including seven of the nine 
members of this family. The finding that Src-family kinases are sufficient to drive resistance to 
EGFR inhibition in an EGFR-mutant setting is in line with considerable evidence linking EGFR 
activity with this family: c-Src itself has been characterized extensively with respect to its 
cooperative relationship with EGFR [37], and Src-family kinase activation has been observed in 
and proposed to be a contributor to cetuximab-resistant colorectal adenocarcinoma and NSCLC 
squamous cell carcinoma in vitro models [38,39], as well as EGFR-TKI-resistant lung 
adenocarcinoma models [40].  Moreover, recent work suggests that the introduction of 
dominant-active c-Src can reduce the inhibitory effects of erlotinib in head and neck squamous 
cell carcinoma models [41]. 
 Similarly, we noted that the fibroblast growth factor receptor (FGFR)-family kinase genes 
FGFR1 and FGFR2, while not previously recognized as sufficient for EGFR bypass, 
nonetheless align with previous work describing upregulation of FGFR1 as well as the ligand 
FGF2 in gefitinib-resistant NSCLC models, with concomitant dependency on the FGFR pathway 
[42,43], as well as other studies implicating FGF ligands in TKI resistance [24,44]. In one recent 
study, a growth factor-based screen for drug resistance identified FGF, the ligand for these 
receptors, as sufficient to partially or completely rescue sensitivity to erlotinib in several EGFR-
mutant cell line models, including PC9 [24]. Incidentally, this concordance also supports the 
notion that cDNA-based screens, which primarily interrogate cell-autonomous mechanisms of 
resistance, can nevertheless complement ligand- or growth factor-based rescue screens in 
nominating pathways important for non-cell-autonomous, microenvironment-driven resistance. 
 Other resistance-inducing genes, including the neurotrophic tyrosine kinase receptor 
(NTKR)-family kinases NTRK1 and NTRK2, MST1R, and the serine/threonine kinases MOS and 
RAF1, have not previously been appreciated to drive TKI resistance in EGFR-mutant lung 
cancer cells, and thus underscore the power of this screening approach in identifying novel 
mediators of bypass for a given dependency. 
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 When viewed collectively, our screening findings reveal a surprisingly extensive list of 
kinase and kinase-related genes with compensatory potential in the setting of oncogene-
addicted EGFR. The finding that a large number of kinase inputs are capable of redundantly 
driving cancer cell growth is consistent with recent reports describing broad compensatory 
potential for growth factor-mediated inhibitor resistance in several tumor dependency models 
[23,24], and with the observation that coactivation of multiple RTKs in glioblastoma cells 
overcomes reliance on any single RTK for downstream signaling activation [25].  
 Finally, in querying somatic mutation and copy number alteration data from over 400 
lung adenocarcinoma cases, we identified significantly co-occurring alterations in EGFR and 
resistance-mediating genes FGR and LCK. The consequence of this co-occurring pattern 
remains to be determined, but based on our in vitro data, one may hypothesize that these 
patients may be more likely to fail or experience a worse outcome on erlotinib treatment than 
EGFR-mutant patients lacking concurrent amplification of FGR and LCK. Analysis of pre- and 
post-relapse biopsy specimens will likely be critical in deducing the exact role this co-occurring 
pattern may play in TKI resistance.  
 Together, our findings uncover the spectrum of kinases sufficient to bypass dependence 
on EGFR in EGFR-mutant lung cancer cells and nominate two genes with potentially immediate 
clinical relevance. 
 
 
 
 
 
 
 
49 
 
MATERIALS AND METHODS 
 
Cell culture and reagents 
 The EGFR-mutant NSCLC cell line PC9 (del E746_A750) has been described previously 
[45]. Cells were maintained in RPMI (Cellgro) supplemented with 10% FBS (Gemini 
Bioproducts). Erlotinib, dasatinib, and lestaurtinib were purchased from LC Laboratories; XL880, 
NVP-BGJ398, and AZ628 were purchased from Selleck Chemicals. Lapatinib was purified from 
patient-discarded tablets by James Bradner. 
 
Kinase ORF screen 
 Screening was performed using a kinase ORF library of 589 ORFs encoding 584 genes 
(Center for Cancer Systems Biology (CCSB)/Broad Institute Kinase Open Reading Frame 
Collection) [28,29], along with the positive and negative controls described in the main text and 
displayed in Figure 1-1. PC9 cells were seeded overnight in 384-well microtiter plates at a 
density of 400 cells per well. The following day, cells were incubated with lentivirus 
corresponding to the kinase ORF library and controls in the presence of 4 µg/mL polybrene, 
spin-infected at 2200 rpm for 30min at 30°C, then incubated at 37°C for an additional 4.5h 
before replacing media with standard growth media. At 24h post-infection, standard growth 
media (6 replicates) or media containing 2 µg/mL blasticidin (1 replicate) was spiked into wells. 
At 72h post-infection, media was replaced with media containing 3 µM erlotinib (2 replicates), 
300 nM erlotinib (2 replicates), DMSO (2 replicates), or DMSO + 2 µg/mL blasticidin (1 
blasticidin-treated replicate). Cell viability was assayed 3d after the addition of erlotinib/DMSO 
using the CellTiter-Glo reagent (Promega).  
 
Identification of candidate resistance-mediating genes 
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 Raw luminescence values representing cell viability were averaged between replicates, 
following exclusion of wells failing detection or other quality control criteria (0.5% of wells). For 
each of the two drug dose screening arms, for a given ORF or control, viability under erlotinib 
treatment was normalized to that under DMSO treatment. Candidate resistance-inducing genes 
were defined as those having relative viability values of at least 39% in 300 nM erlotinib and at 
least 31% in 3 µM erlotinib. Luminescence values corresponding to DMSO + blasticidin-treated 
cells were also compared to those of (unselected) DMSO-treated cells to assess each ORF’s 
infection efficiency (data not shown). 
 
Screen validation and drug sensitivity assays 
 PC9 cells were seeded overnight in 384-well microtiter plates at a density of 400 cells 
per well. The following day, cells were incubated with lentivirus (virus production methods 
described below) corresponding to candidate resistance-mediating ORFs as well as controls in 
the presence of 4 µg/mL polybrene, spin-infected at 2200 rpm for 30min at 30°C, then incubated 
at 37°C for an additional 4.5h before replacing media with standard growth media. At 24h post-
infection, additional standard growth media was spiked into wells. At 72h post-infection, media 
was replaced with media containing inhibitor(s) at their final concentrations or DMSO (1:1,000 
dilution). For dose-response curves, inhibitor(s) were tested at each of the following 
concentrations: 10, 1, 0.1, 0.01, 0.001, and 0.0001 µM. Cell viability was assayed 3d after the 
addition of inhibitor(s) or DMSO using CellTiter-Glo (Promega). Drug-treated cells were 
normalized to DMSO-treated cells to calculate relative percent viability. Relative percent viability 
values and dose-response curves were plotted using GraphPad Prism software (GraphPad); 
area under curve values were generated using GraphPad Prism software and displayed using 
GENE-E software. Absolute IC50 values were calculated using GraphPad Prism software. 
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Virus production  
 Lentivirus was produced by transfection of 293T packaging cells with plasmids 
corresponding to pLX-Blast-V5-ORF, Δ8.9 (gag, pol), and VSV-G; and FuGene6 transfection 
reagent (Roche) as described previously [29].  
 
Viral transduction and culture of ORF-expressing cells for protein analysis 
 Cells were seeded in 6-well plates at a density of 54,000 cells per well. The next day, 
cells were incubated with lentivirus in the presence of 4 µg/mL polybrene for 6-7h, after which 
media was replaced with standard growth media. At 24h post-infection, media was replaced 
with selective media containing 1-1.3 µg/mL blasticidin, and blasticidin-containing media was 
replenished after another 72h. At 6d post-infection, cells were treated with media containing 
0.5% FBS overnight. The following day, cells were treated with inhibitor(s) or DMSO at their final 
concentrations in media containing 0.5% FBS for 6h, then harvested for immunoblotting. 
 
Immunoblotting 
 Cell pellets were resuspended in lysis buffer (50 mM Tris pH 7.4, 2.5 mM EDTA pH 8, 
150 mM NaCl, 1% Triton X-100, 0.25% IGEPAL CA-630), supplemented with protease inhibitors 
(Roche) and Phosphatase Inhibitor Cocktails I and II (Calbiochem), incubated on ice for 2 min, 
then centrifuged for 2 min at 13,000 rpm. The protein concentrations of supernatants were 
determined using a BCA Protein Assay Kit (Pierce) and normalized. Lysates were reduced and 
denatured, then separated using Tris-Glycine gels (Novex) and transferred to iBlot Transfer 
Stack nitrocellulose membranes (Novex). Membranes were incubated with primary antibodies 
overnight at 4°C. Antibodies against phospho-EGFR (Y1068) (1:1,000) and V5 (1:5,000) were 
purchased from Invitrogen. The antibody recognizing total EGFR (1:1,000) was purchased from 
BD Biosciences. Antibodies against total AKT (1:1,000), phospho-AKT (S473 and T308), total 
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ERK1/2 (1:750), phospho-ERK1/2 (T202/Y204) (1:500), and cofilin (1:10,000) were purchased 
from Cell Signaling Technology. Phospho-AKT immunoblotting was performed with the S473-
directed antibody (1:750) unless otherwise indicated. Incubation with IRDye secondary 
antibodies (1:10,000) (LI-COR Biosciences) and subsequent detection (Odyssey Imaging 
System, LI-COR Biosciences) were performed according to manufacturer recommendations. 
 
Analysis of lung adenocarcinoma patient tumors 
 TCGA copy number and mutation data were obtained from the Broad Institute TCGA 
Firehose pipeline (doi:10.7908/C1Z60M5H); and somatic alteration data for the validation cohort 
were obtained from [35]. The sample set and somatic variant calling pipelines used to generate 
both datasets are described in (TCGA paper, submitted, and [35]). Briefly, somatic mutations 
(substitutions, insertions, deletions) were identified through comparison of matched tumor and 
normal whole-exome sequencing alignments [46]; and somatic copy number alterations were 
derived through GISTIC 2.0 pre-processing of Affymetrix SNP 6.0 profiles of tumor and matched 
normal DNA [47]. For heatmap and statistical analyses, a gene was designated as harboring a 
copy gain or loss in a tumor sample if the average relative copy number change across its 
length was >0.3 or < -0.3, respectively; and mutation data represent non-silent somatic 
mutations. Mutations in EGFR were further designated as “activating” if they met one of the 
following criteria: any deletion in exon 19; any insertion in exon 20; any mutations at residues 
858, 719, 861, 768, 769, or 709 [31]; or any substitution within exons 18-21 that generated a 
PolyPhen-2 score of >0.9 [48]. For a list of non-silent somatic EGFR mutations present in these 
datasets and their characterization as activating or (non-activating) missense, see Table 1-2. 
 
Statistical tests 
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 One-tailed Fisher’s exact tests, odds ratios, and 95% confidence intervals were 
calculated using GraphPad Prism software. P-values less than 0.01 were considered significant. 
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CHAPTER 2 
 
A Gene-Expression-Based Approach to Identify Chemical Modifiers of EGFR Dependence 
 
 
 
 
 
 
 
 
Attributions: 
Portions of this chapter are reprinted from a manuscript in preparation. 
All experiments and analyses were performed by Tanaz Sharifnia except as follows: 
LINCS queries, and analyses represented in Figures 2-1A and 2-1C were designed and performed by 
Victor Rusu and Aravind Subramanian. Data visualization for Figures 2-1A, 2-2, 2-3, and 2-6A was done 
by Bang Wong and Tanaz Sharifnia. 
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ABSTRACT 
 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective 
therapies in the subset of non-small cell lung cancers with EGFR mutations, but clinical benefit 
is limited by the development of drug resistance. Previous work has identified 18 kinase and 
kinase-related genes whose overexpression can induce resistance to EGFR inhibition in EGFR-
mutant NSCLC cells, but whether these EGFR bypass genes have shared functional effects is 
not known. In this study, we applied an unbiased gene-expression-based connectivity approach 
(Library of Integrated Network-based Cellular Signatures resource) to determine whether 
resistance-mediating genes act through common or divergent pathways, and to identify 
compounds that may reverse erlotinib resistance. Gene-expression analysis of cells 
overexpressing resistance-mediating genes, together with targeted validation studies, implicates 
the phosphoinositide 3-kinase (PI3K)-AKT and MEK-ERK pathways as active in these cells 
under erlotinib treatment. Combined treatment with the PI3K-mTOR inhibitor NVP-BEZ235 and 
MEK inhibitor AZD6244 restores erlotinib sensitivity of cells expressing all 18 resistance-
inducing genes. Using this connectivity approach, we also identified two chemical compounds, 
the cardiac glycoside helveticoside and the NEDD8-activating enzyme inhibitor MLN4924, that 
can reduce EGFR dependence in EGFR-TKI-sensitive cells. Together, these data suggest that 
resistance-mediating genes commonly induce similar transcriptional effects, and that combined 
MEK and PI3K-mTOR inhibition may be an effective and universal strategy for overcoming 
kinase-driven resistance to EGFR-TKIs. 
 
INTRODUCTION  
 Activating mutations in the epidermal growth factor receptor (EGFR) are a common 
driver alteration in non-small cell lung cancer [1,2,3,4,5] and can predict sensitivity to the EGFR 
tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib [6,7,8,9], but all patients eventually 
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develop resistance to therapy [10]. We have previously described an open reading frame 
(ORF)-based screen to identify the spectrum of kinases whose overexpression can induce 
erlotinib resistance in EGFR-mutant NSCLC cells (Chapter 1). An unexpected finding of this 
work was the breadth and diversity of kinase and kinase-related genes capable of substituting 
for EGFR in the setting of EGFR dependence: 18 kinase and kinase-related genes were 
identified in this screen, and this set of genes included several tyrosine kinase subfamilies of 
both receptor and non-receptor kinase classes, as well as serine/threonine kinases.  
 Given the broad subset of kinase genes that could induce erlotinib resistance in these 
cells, we were interested in identifying signaling pathways that were potentially common to 
overexpression of these genes; in principle, such pathways might be targets for a generalized 
strategy to overcome erlotinib resistance. A hypothesis-driven analysis described in Chapter 1 
indicated a role for activation of the AKT pathway (Chapter 1, Figure 1-4B-G); however, an 
unbiased systematic approach might more clearly address whether resistance-inducing genes 
act through common or divergent pathways.  
 We reasoned that a high-dimensional transcriptional readout would provide an unbiased 
approach to address this question. Gene-expression profiling methods have been used 
extensively over the last 15 years to classify disease subtypes [11,12,13,14,15,16], identify new 
drug targets [12,17], and predict clinical outcome or response to therapy [18,19,20,21]. In recent 
years, large gene-expression catalogs, such as the resource created by the Library of 
Integrated Network-based Cellular Signatures (LINCS) Connectivity Map project 
(lincscloud.org), have allowed investigators to identify functional relationships between genes, 
drugs, or diseases on the basis of their shared transcriptional effects [22,23]. In this study, we 
have applied a gene expression-based approach using the Connectivity Map resource to detect 
commonalities between erlotinib resistance-mediating genes and to identify chemical 
compounds that can modify the resistant state.                                                                                                      
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RESULTS 
Resistance-mediating genes commonly induce similar transcriptional effects 
 We assembled reagents for the 18 resistance-mediating genes (positive-phenotype 
genes) as well as 19 kinase genes that had failed to rescue erlotinib sensitivity (negative-
phenotype genes) in the previously-described ORF screen (Chapter 1). PC9 cells were 
transduced with positive-phenotype, negative-phenotype, and control vectors for 72h, after 
which they were subjected to 24h erlotinib treatment. Gene-expression profiles for each ORF 
were generated in quadruplicate and used to compute signatures as described in Materials and 
Methods.  
 Unsupervised hierarchical clustering of these signatures yielded two distinct clusters 
(Figure 2-1A). Intriguingly, profiles showed a pattern of segregation largely in accordance with 
resistant versus sensitive phenotypes; in particular, we observed one subcluster comprised 
solely of 12 resistance-associated profiles and the two EGFR double-mutant positive controls 
included in the assay, labeled red in Figure 2-1A. Given that this cluster contained almost all 
resistance-associated gene profiles and none of the negative-phenotype profiles, we chose to 
focus our subsequent analyses on the profiles represented therein, henceforth referred to as the 
‘positive-phenotype cluster.’  
 We next asked if the expression profiles of cells transduced with resistance-associated 
ORFs could yield insights into their biological effects. To investigate this, we turned to an 
expression-profiling resource created by the Library of Integrated Network-based Cellular 
Signatures (LINCS) program (lincscloud.org). The LINCS database is a large catalog of gene-
expression profiles generated from diverse human cell lines (A549, MCF7, PC3, A375, HepG2, 
VCaP, HCC515, HT29) treated with a large number of genetic and chemical perturbagens 
(lincscloud.org). Gene-expression signatures from cells expressing each of the 12 genes 
represented in the positive-phenotype cluster (excluding controls) were independently used to 
query LINCS.  
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 We first sought to identify ORFs in the LINCS dataset whose transcriptional effects most 
positively-correlate with query ORFs. We hypothesized that identifying LINCS ORFs whose 
signatures positively-correlate with query ORFs could lend insight into whether resistance-
mediating ORFs act through shared or distinct pathways. When considering the top ~3% of 
positively-correlated ORFs (Figure 2-1B), we observed that our query ORF signatures 
commonly correlate with other signatures generated using these same ORFs or from other 
positive-phenotype cluster members. These findings were particularly notable as none of the 
cell lines profiled in the LINCS dataset is EGFR-mutant, and most are not of a lung lineage. 
Together with the hierarchical clustering, these data suggest that a major subset of resistance-
mediating genes induce similar transcriptional effects, and these effects do not appear to be 
restricted to an EGFR-mutant cellular context. 
 In order to identify genes that were differentially expressed between positive-phenotype 
cluster genes and genes unable to confer erlotinib resistance, a two-class comparison was 
performed on these two groups (Figure 2-1C). We observed that a large number of genes are 
significantly differentially expressed between these two classes (signal-to-noise ratios of > 2 or 
< -2). Genes that were expressed more highly in the positive-phenotype (erlotinib-resistant) 
class included DPH2, FOSL1, MYC, CDC25A, PNP, PSMG1, and MCM3, among others. Genes 
with lower expression in the positive-phenotype class included ERBB3, TRAPPC6A, FOXO4, 
IGFBP3, and CBLB, among others. Together, these genes help to define the transcriptional 
signature commonly associated with resistance-mediating ORFs. 
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Figure 2-1. Resistance-mediating genes induce similar transcriptional effects.  (A) 
Unsupervised hierarchical clustering of PC9 cells overexpressing resistance-mediating ORFs 
(“+”); kinase ORFs unable to confer erlotinib resistance (“-”); and EGFR double-mutant positive 
controls and inert gene negative controls (“C”). Twelve resistance-mediating ORFs displaying 
membership in a single cluster (‘positive-phenotype cluster,’ labeled red) were used to query the 
LINCS dataset. (B) LINCS ORFs whose signatures most positively-correlate with those of  
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Figure 2-1 (Continued) 
positive-phenotype cluster genes. Each of the twelve positive-phenotype genes was used to 
independently query the LINCS dataset, and the top ~3% positively-correlated ORFs are listed. 
Query ORFs commonly ‘connect’ with themselves or other positive-phenotype cluster members. 
(C) Two-class comparison of ‘positive-phenotype cluster’ members and kinase ORFs unable to 
confer erlotinib resistance. The top and bottom 50 differentially expressed genes are listed, 
along with their respective signal-to-noise ratios. 
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Transcriptional effects induced by resistance-promoting genes are anti-correlated to 
those induced by MEK and PI3K inhibitors 
 In addition to signatures generated from genetic perturbagens, the LINCS database 
contains over 34,000 gene-expression profiles collected from human cells treated with 3,103 
chemical reagents. Using this resource, we next asked if the expression profiles of cells 
transduced with resistance-associated ORFs could be used to nominate chemical compounds 
with potential to reverse ORF-mediated resistance.  
 As described above, gene-expression signatures from cells expressing each of the 12 
genes represented in the positive-phenotype cluster (excluding controls) were independently 
used to query LINCS. In this case, we looked for chemical perturbations whose transcriptional 
effects were anti-correlated with those of resistance-promoting genes, hypothesizing that such 
perturbations could pinpoint pathways or mechanistic nodes distinctly active in resistant cells, as 
well as nominate compound classes with potential to reverse ORF-mediated resistance. Among 
the top 0.7% anti-correlated compounds (Figure 2-2, blue portion of barcode plot), 13 out of the 
21 compounds (>61%) could be classified as either MEK or PI3K inhibitors (Figure 2-2, 
expanded view). These two drug targets, along with the third-most abundant target, SRC, were 
the only recurrent drug targets represented at the top of this list (Figure 2-3). The enrichment of 
these two inhibitor classes indicated that the cell states induced by our panel of resistance-
promoting query genes were opposed to those induced by PI3K or MEK inhibition, and 
conversely suggested that either or both of these pathways could be active in resistant cells. 
The similarity in profiles observed via unsupervised clustering, along with the observed 
correlations to a shared set of LINCS compound signatures, suggests that the erlotinib 
resistance-promoting genes identified in our screen could mechanistically converge on a small 
number of signaling nodes. 
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Figure 2-2. Transcriptional effects induced by resistance-mediating ORFs negatively-
correlate with those induced by MEK and PI3K inhibitors. Barcode plot displaying LINCS 
compounds ranked by the correlations of their signatures to those of ‘positive-phenotype cluster’ 
ORFs. The most positively/negatively-correlated compounds approach ranks of 1 and -1 
respectively. The 0.7% most negatively-correlated compounds (blue portion of barcode plot) 
include several inhibitors targeting MEK, PI3K, and SRC (Figure 2-3). Each bar represents a 
chemical reagent. A single reagent targeting both PI3K and SRC is denoted with an asterisk.  
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Figure 2-3. LINCS compounds whose transcriptional effects most negatively-correlate 
with those of resistance-mediating ORFs. Median normalized ranks of the top 0.7% 
negatively-correlated compounds and categorization by drug target class and primary target(s) 
(References [24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40]). Each bar represents a 
compound. A single compound targeting both PI3K and SRC is denoted with an asterisk. 
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Resistance-promoting ORFs commonly reactivate phospho-AKT and/or phospho-
ERK1/2, and combined inhibition of PI3K-mTOR and MEK rescues ORF-mediated 
resistance to erlotinib 
 Given the identification of PI3K and MEK inhibitor treatment signatures as anti-correlated 
with our ‘positive-phenotype’ erlotinib resistance signatures (Figure 2-2), we sought to address 
whether resistance-inducing ORF genes confer erlotinib resistance via reactivation of the PI3K-
AKT or MEK-ERK pathways. PC9 cells overexpressing resistance-inducing genes were treated 
with increasing doses of erlotinib for 6h and profiled for activation of EGFR, AKT, and ERK1/2 
by immunoblot analysis (Figure 2-4A). Indeed, persistent activation of AKT and/or ERK1/2 
under erlotinib treatment is a common feature of the majority of resistance-inducing ORFs, with 
sustained phospho-AKT most prominently associated with expression of several Src-family 
kinases (BLK, FGR, FRK, HCK, LCK, and SRC itself), ITK, and CRKL; and sustained phospho-
ERK1/2 most prominently associated with RAF1, BLK, ITK, MOS, AXL, and CRKL. Other ORFs, 
such as those encoding FGFR-family genes, appear to display very modest activation of one or 
both of these pathways, which may also be reflective of their more modest rescue phenotype 
(Chapter 1, Figure 1-1). Interestingly, we also observed that cells expressing several kinase 
genes maintain phosphorylation of EGFR itself in the presence of erlotinib, and these include 
BLK, LCK, FGR, and FRK. 
 To determine whether reactivation of these signal transducers is required for ORF-
associated resistance, cells transduced with resistance-promoting genes were treated with 
erlotinib; the dual PI3K-mTOR inhibitor NVP-BEZ235 (hereafter referred to as BEZ235); the 
MEK inhibitor AZD6244; or their combinations, and assayed for cell viability after 72h (Figure 2-
4B). Drug doses of BEZ235 (500 nM) and AZD6244 (2.5 µM) were determined empirically to be 
the lowest doses capable of maximally inhibiting AKT and ERK1/2 phosphorylation (Figure 2-5), 
and are in similar ranges to those used by other investigators in EGFR-mutant cell lines [41].  
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Figure 2-4. Resistance-mediating ORFs commonly reactivate phospho-AKT and/or 
phospho-ERK1/2, and PI3K-mTOR and MEK co-inhibition restores sensitivity to erlotinib. 
(A) Immunoblot analysis of PC9 cells overexpressing the indicated ORFs and treated with 
erlotinib for 6h. Cells were incubated with 0.5% serum media 18h before and during drug/DMSO 
treatment. Total cell lysates were immunoblotted for the indicated proteins. (B) Cell viability of 
PC9 cells overexpressing the indicated ORFs following treatment with 100nM erlotinib (erl), 500 
nM of the PI3K-mTOR inhibitor BEZ235 (BEZ), 2.5 µM of the MEK inhibitor AZD6244 (AZD), or 
their combinations for 72h. Cell viability was assayed with CellTiter-Glo. Data are expressed as 
percent viability relative to vehicle-treated cells and represent the mean ± SD of 4 replicates. 
 
69 
 
 
 
Figure 2-5. BEZ235 and AZD6244 treatment downregulate phospho-AKT and phospho-
ERK1/2, respectively, in a dose-dependent fashion. (A) Immunoblot analysis of PC9 cells 
treated with indicated doses of the PI3K-mTOR inhibitor BEZ235 for 6h. Total cell lysates were 
immunoblotted for the indicated proteins. (B) Immunoblot analysis of PC9 cells treated with 
indicated doses of the MEK inhibitor AZD6244 for 4h. Total cell lysates were immunoblotted for 
the indicated proteins.  
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We observed that combined BEZ235 and AZD6244 treatment was sufficient to restore 
sensitivity to erlotinib across all ORF-expressing cell lines, with sensitivity often enhanced 
relative to erlotinib treatment in LACZ-expressing cells. We also noted that in cases where at 
least partial restoration of erlotinib sensitivity could be achieved using either BEZ235 or 
AZD6244, re-sensitization was always potentiated by combining these two agents. Together, 
these data demonstrate that reactivation of AKT and ERK1/2 signaling commonly underlies, and 
is required for, ORF-mediated resistance. 
Compounds whose transcriptional effects positively-correlate with those of resistance-
promoting genes can reduce dependence on EGFR 
 Intriguingly, the LINCS query described above also revealed the existence of chemical 
perturbations whose transcriptional effects were positively-correlated with those of resistance-
promoting genes. We hypothesized that at least some subset of these chemical compounds 
could, as with resistance-mediating ORFs, reduce dependence on EGFR in EGFR-mutant cells. 
The most positively-correlated compounds (corresponding to the top 0.2% of all compounds) 
are displayed in Figure 2-6A (expanded view). They include the cardiac glycoside helveticoside 
[42], the NEDD8-activating enzyme inhibitor MLN4924 [43], the anti-proliferative agent kinetin 
riboside [44,45], the microtubule inhibitors nocodazole [46] and CYT997[47], and the PKC 
activator ingenol [48]. To determine whether positively-correlating compounds, like resistance-
mediating ORFs, could reduce erlotinib sensitivity, PC9 cells were treated with increasing 
concentrations of these compounds, in combination with either erlotinib (500 nM or 1 μM in 
parallel) or DMSO (Figure 2-6B). Remarkably, we observed that the highest-scoring 
compounds, helveticoside and MLN4924, indeed conferred a modest, dose-dependent increase 
in cell viability in the presence of erlotinib, relative to erlotinib-treatment alone. In contrast, these 
compounds did not increase cell viability in the presence of DMSO, suggesting that their effects 
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are not generally growth-enhancing. The ability of other positively-correlated compounds to 
increase cell viability in the presence of erlotinib was less apparent (Figure 2-6B).  
 These results indicate that in some cases chemical perturbagens whose transcriptional 
effects are shared with resistance-promoting genes also share the ability to reduce dependence 
on EGFR. As with the LINCS ORF query described in Figure 2-1, this is the case despite the 
diverse cell line backgrounds used to generate gene-expression signatures. Using this 
approach, we have identified two compounds with a previously unappreciated ability to modify 
dependence on EGFR. 
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Figure 2-6. LINCS compounds whose transcriptional effects most positively-correlate 
with those of resistance-mediating ORFs. (A) Barcode plot displaying LINCS compounds  
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Figure 2-6 (Continued)                                                           
ranked by the correlations of their signatures to those of ‘positive-phenotype cluster’ ORFs, as 
described in Figure 2-2. The top 0.2% most positively-correlated compounds are displayed in 
the expanded view and are annotated by compound class (References [42,43,44,45,46,47,48]). 
Each bar represents a chemical reagent. NAE, NEDD8-activating enzyme. (B) Positively-
correlated compounds’ effects on EGFR dependence. PC9 cells were treated with DMSO, 500 
nM erlotinib, or 1 μM erlotinib, in combination with either vehicle or increasing concentrations of 
the query compound. Cell viability was assayed after 72h using CellTiter-Glo. Data are 
expressed as percent viability relative to DMSO- or erlotinib-treated cells in combination with 
vehicle. Data represent the mean ± SD of 4 replicates. 
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DISCUSSION 
 This study has applied a gene-expression-based approach to functionally characterize a 
set of kinase and kinase-related genes whose overexpression can bypass dependence on 
EGFR (see Chapter 1). The finding that a broad set of kinase inputs can redundantly drive 
cancer cell growth has been observed in several tumor dependency models in addition to that of 
EGFR [49,50,51] and led us to ask whether these bypass genes act through distinct or shared 
signaling pathways in conferring the resistant phenotype. The latter case would imply that 
targeting a shared pathway might serve as a generalized strategy to overcome kinase-mediated 
erlotinib resistance, irrespective of the specific kinase responsible for EGFR bypass. 
 Using an unbiased gene-expression readout, we observed that resistance-mediating 
genes commonly induce similar gene-expression signatures, distinguishable from those of 
kinases unable to mediate erlotinib resistance. More strikingly, when queried against all ORFs in 
the LINCS dataset, resistance-mediating ORFs often ‘connect’ most strongly to each other, 
even across highly diverse genetic contexts. 
 Querying the LINCS dataset also allowed us, in an unbiased fashion, to nominate MEK 
and PI3K as selectively active in resistant versus sensitive cells, and this finding was 
corroborated with immunoblot analysis demonstrating that resistance ORF-expressing cells 
commonly reactivate one or both of these signaling pathways under erlotinib treatment. 
Importantly, the re-engagement of these pathways was required for erlotinib resistance, as 
evidenced by restoration of erlotinib sensitivity for all resistance-mediating ORFs with combined 
AZD6244 and BEZ235 inhibitor treatment. That is, we found that despite the breadth and 
diversity of kinases capable of overcoming inhibition of EGFR in this context, these genes are 
remarkably uniform in their convergence upon the PI3K-AKT and/or MEK-ERK pathways. 
 Finally, we have identified two compounds, the cardiac glycoside helveticoside and the 
NEDD8-activating enzyme inhibitor MLN4924, that can reduce sensitivity to EGFR inhibition in 
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erlotinib-sensitive cells. To our knowledge, this represents the first demonstration of chemical 
suppression of EGFR-TKI sensitivity. These findings warrant further study to dissect the 
mechanism by which these compounds can modify EGFR dependence. 
 Collectively, these data identify transcriptional similarities between resistance-mediating 
ORFs and underscore these genes’ convergence on the PI3K-AKT and MEK-ERK signaling 
axes in sustaining EGFR-independent survival. 
 
MATERIALS AND METHODS  
 
Cell culture and reagents 
 The EGFR-mutant NSCLC cell line PC9 (del E746_A750) has been described previously 
[52]. Cells were maintained in RPMI (Cellgro) supplemented with 10% FBS (Gemini 
Bioproducts). Erlotinib was purchased from LC Laboratories; AZD6244, NVP-BEZ235, CYT997, 
nocodazole, and MLN4924 were purchased from Selleck Chemicals; kinetin riboside and 
ingenol were purchased from Santa Cruz Biotechnology; helveticoside was purchased from 
MolPort. 
 
Virus production  
 Lentivirus was produced by transfection of 293T packaging cells with plasmids 
corresponding to pLX-Blast-V5-ORF, Δ8.9 (gag, pol), and VSV-G; and FuGene6 transfection 
reagent (Roche) as described previously [53]. 
  
Gene-expression profiling and LINCS analysis 
 ORFs selected for profiling included 18 validated resistance-promoting ORFs; 19 kinase 
ORFs unable to confer erlotinib resistance in the primary ORF screen (as measured by a z-
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score less than 0.2 under both drug doses) (Chapter 1); as well as controls. PC9 cells were 
seeded overnight in 384-well microtiter plates at a density of 400 cells per well. The following 
day, cells were incubated with lentivirus corresponding to ORFs in the presence of 4 µg/mL 
polybrene, spin-infected at 2200 rpm for 30min at 30°C, then incubated at 37°C for an additional 
4.5h before replacing media with standard growth media. At 24h post-infection, additional 
standard growth media was spiked into wells. At 72h post-infection, media was replaced with 
media containing 300 nM erlotinib. After 24h of drug treatment, media was aspirated and 
replaced with TCL Buffer (Qiagen) for cell lysis. Plates were incubated at 25°C for 25 min, then 
stored at -80°C until gene-expression profiling steps.  
 Gene-expression profiles consisted of 978 transcripts that were selected by the LINCS 
program (lincscloud.org) to represent an unbiased reduced representation of the transcriptome 
and measured using a Luminex bead-based system [54]. Each ORF was assayed and profiled 
in quadruplicate and all expression data were quantile-normalized. To quantify the magnitude of 
differential expression in our data we computed robust z-scores for each gene in each sample 
according to, 
z୧ ൌ X୧ െ medianሺYሻMADሺYሻ ൈ 1.4826 
where X୧ is the scaled expression value of the sample of interest, Y is the vector of observed 
control expression values for the gene of interest, and MAD is the mean absolute deviation.  
 After computing a robust z-score vector for each replicate, we combined the robust z-
scored replicate vectors into a single representative vector that we refer to as a signature.  
Unsupervised hierarchical clustering using the Spearman correlation metric was performed on 
signatures generated from PC9 cells expressing 18 resistance-inducing genes, 19 kinases 
unable to induce resistance, and controls. Hierarchical clustering revealed a tight cluster 
comprised of 12 resistance-promoting genes and the 2 EGFR double-mutant positive controls. 
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Querying the compound signatures in the LINCS dataset was performed as follows: signatures 
from each of the 12 resistance-promoting genes were used to independently query compound 
signatures in the LINCS dataset. Each compound–ORF query pair was assigned a connectivity 
score [23] computed using the weighted Kolmogorov-Smirnov statistic [55]. All compounds in 
the dataset were rank-ordered by their connectivity scores to a given ORF query. To identify 
compounds that were consistently correlated/anti-correlated to the query ORFs, we computed 
every compound’s median normalized rank across all 12 ORFs. The resultant ranks are 
displayed in Figure 2-2. An analogous analysis was performed to query the ORF signatures in 
the LINCS dataset. 
 Comparative marker selection analysis was performed using GENE-E software. 
  
Viral transduction and culture of ORF-expressing cells for protein analysis 
 Cells were seeded in 6-well plates at a density of 54,000 cells per well. The next day, 
cells were incubated with lentivirus in the presence of 4 µg/mL polybrene for 6-7h, after which 
media was replaced with standard growth media. At 24h post-infection, media was replaced 
with selective media containing 1-1.3 µg/mL blasticidin, and blasticidin-containing media was 
replenished after another 72h. At 6d post-infection, cells were treated with media containing 
0.5% FBS overnight. The following day, cells were treated with inhibitor(s) or DMSO at their final 
concentrations in media containing 0.5% FBS for 6h, then harvested for immunoblotting. 
 
Immunoblotting 
 Cell pellets were resuspended in lysis buffer (50 mM Tris pH 7.4, 2.5 mM EDTA pH 8, 
150 mM NaCl, 1% Triton X-100, 0.25% IGEPAL CA-630), supplemented with protease inhibitors 
(Roche) and Phosphatase Inhibitor Cocktails I and II (Calbiochem), incubated on ice for 2 min, 
then centrifuged for 2 min at 13,000 rpm. The protein concentrations of supernatants were 
determined using a BCA Protein Assay Kit (Pierce) and normalized. Lysates were reduced and 
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denatured, then separated using Tris-Glycine gels (Novex) and transferred to iBlot Transfer 
Stack nitrocellulose membranes (Novex). Membranes were incubated with primary antibodies 
overnight at 4°C. The antibody against phospho-EGFR (Y1068) (1:1,000) was purchased from 
Invitrogen. The antibody recognizing total EGFR (1:1,000) was purchased from BD Biosciences. 
Antibodies against total AKT (1:1,000), phospho-AKT (S473, 1:750), total ERK1/2 (1:750), and 
phospho-ERK1/2 (T202/Y204) (1:500) were purchased from Cell Signaling Technology. 
Incubation with IRDye secondary antibodies (1:10,000) (LI-COR Biosciences) and subsequent 
detection (Odyssey Imaging System, LI-COR Biosciences) were performed according to 
manufacturer recommendations. 
 
Drug sensitivity assays 
 For drug sensitivity assays of ORF-expressing cells: PC9 cells were seeded overnight in 
384-well microtiter plates at a density of 400 cells per well. The following day, cells were 
incubated with lentivirus (virus production methods described above) corresponding to 
candidate resistance-mediating ORFs as well as controls in the presence of 4 µg/mL polybrene, 
spin-infected at 2200 rpm for 30min at 30°C, then incubated at 37°C for an additional 4.5h 
before replacing media with standard growth media. At 24h post-infection, additional standard 
growth media was spiked into wells. At 72h post-infection, media was replaced with media 
containing inhibitor(s) at their final concentrations or DMSO (1:1,000 dilution). For drug 
sensitivity assays of parental cells: PC9 cells were seeded overnight in 384-well microtiter 
plates at a density of 800 cells per well. The following day, cells were treated with media 
containing inhibitor(s) or DMSO.  
 Cell viability was assayed 3d after the addition of inhibitor(s) or DMSO using CellTiter-
Glo (Promega). Drug-treated cells were normalized as described in the figure legends to 
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calculate relative percent viability. Relative percent viability values and dose-response curves 
were plotted using GraphPad Prism software (GraphPad). 
 
 
REFERENCES 
1. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, et al. (2005) Clinical and biological 
features associated with epidermal growth factor receptor gene mutations in lung 
cancers. J Natl Cancer Inst 97: 339-346. 
2. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, et al. (2004) EGFR mutations in lung 
cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. 
3. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, et al. (2004) Activating 
mutations in the epidermal growth factor receptor underlying responsiveness of non-
small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139. 
4. Pao W, Miller V, Zakowski M, Doherty J, Politi K, et al. (2004) EGF receptor gene mutations 
are common in lung cancers from "never smokers" and are associated with sensitivity of 
tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101: 13306-13311. 
5. Pao W, Hutchinson KE (2012) Chipping away at the lung cancer genome. Nat Med 18: 349-
351. 
6. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, et al. (2009) Screening for epidermal 
growth factor receptor mutations in lung cancer. N Engl J Med 361: 958-967. 
7. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, et al. (2010) Gefitinib or 
chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362: 
2380-2388. 
8. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, et al. (2012) Erlotinib versus 
standard chemotherapy as first-line treatment for European patients with advanced 
EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-
label, randomised phase 3 trial. Lancet Oncol 13: 239-246. 
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, et al. (2009) Gefitinib or carboplatin-
paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957. 
10. Engelman JA, Settleman J (2008) Acquired resistance to tyrosine kinase inhibitors during 
cancer therapy. Curr Opin Genet Dev 18: 73-79. 
11. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular 
classification of cancer: class discovery and class prediction by gene expression 
monitoring. Science 286: 531-537. 
80 
 
12. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, et al. (2002) MLL 
translocations specify a distinct gene expression profile that distinguishes a unique 
leukemia. Nat Genet 30: 41-47. 
13. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, et al. (2001) Classification of 
human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma 
subclasses. Proc Natl Acad Sci U S A 98: 13790-13795. 
14. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, et al. (2000) Distinct types of diffuse 
large B-cell lymphoma identified by gene expression profiling. Nature 403: 503-511. 
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, et al. (2000) Molecular portraits of 
human breast tumours. Nature 406: 747-752. 
16. Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, et al. (2010) Integrated genomic 
analysis identifies clinically relevant subtypes of glioblastoma characterized by 
abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110. 
17. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, et al. (2003) Inhibition of 
FLT3 in MLL. Validation of a therapeutic target identified by gene expression based 
classification. Cancer Cell 3: 173-183. 
18. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression 
profiling predicts clinical outcome of breast cancer. Nature 415: 530-536. 
19. Pomeroy SL, Tamayo P, Gaasenbeek M, Sturla LM, Angelo M, et al. (2002) Prediction of 
central nervous system embryonal tumour outcome based on gene expression. Nature 
415: 436-442. 
20. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, et al. (2002) Diffuse large B-cell 
lymphoma outcome prediction by gene-expression profiling and supervised machine 
learning. Nat Med 8: 68-74. 
21. Konstantinopoulos PA, Spentzos D, Karlan BY, Taniguchi T, Fountzilas E, et al. (2010) 
Gene expression profile of BRCAness that correlates with responsiveness to 
chemotherapy and with outcome in patients with epithelial ovarian cancer. J Clin Oncol 
28: 3555-3561. 
22. Lamb J (2007) The Connectivity Map: a new tool for biomedical research. Nat Rev Cancer 
7: 54-60. 
23. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, et al. (2006) The Connectivity Map: 
using gene-expression signatures to connect small molecules, genes, and disease. 
Science 313: 1929-1935. 
24. Wittman M, Carboni J, Attar R, Balasubramanian B, Balimane P, et al. (2005) Discovery of a 
(1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth 
factor I receptor kinase with in vivo antitumor activity. J Med Chem 48: 5639-5643. 
81 
 
25. Fremin C, Meloche S (2010) From basic research to clinical development of MEK1/2 
inhibitors for cancer therapy. Journal of Hematology & Oncology 3. 
26. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, et al. (1998) Identification of 
a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-
18632. 
27. Camps M, Ruckle T, Ji H, Ardissone V, Rintelen F, et al. (2005) Blockade of PI3Kgamma 
suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat 
Med 11: 936-943. 
28. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, et al. (2008) Targeted 
polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. 
Nature Chemical Biology 4: 691-699. 
29. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, et al. (2007) Biological characterization 
of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase 
kinase 1/2 inhibitor. Clin Cancer Res 13: 1576-1583. 
30. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, et al. (2004) 
VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, 
suppresses tumor growth in vivo. Nat Med 10: 262-267. 
31. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, et al. (1996) Discovery of a 
novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-
dependent T cell activation. J Biol Chem 271: 695-701. 
32. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA (2007) Selective Raf inhibition in cancer 
therapy. Expert Opinion on Therapeutic Targets 11: 1587-1609. 
33. Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, et al. (2010) AZD8055 Is a 
Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of 
Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity. Cancer Research 
70: 288-298. 
34. Knight ZA, Gonzalez B, Feldman ME, Zunder ER, Goldenberg DD, et al. (2006) A 
pharmacological map of the PI3-K family defines a role for p110 alpha in insulin 
signaling. Cell 125: 733-747. 
35. Kim K, Kong SY, Fulciniti M, Li XF, Song WH, et al. (2010) Blockade of the MEK/ERK 
signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic 
anti-myeloma activity in vitro and in vivo. British Journal of Haematology 149: 537-549. 
36. Sebolt-Leopold JS, Dudley DT, Herrera R, Van Becelaere K, Wiland A, et al. (1999) 
Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nature 
Medicine 5: 810-816. 
37. Kim HG, Tan L, Weisberg EL, Liu F, Canning P, et al. (2013) Discovery of a Potent and 
Selective DDR1 Receptor Tyrosine Kinase Inhibitor. ACS Chem Biol. 
82 
 
38. Yano H, Nakanishi S, Kimura K, Hanai N, Saitoh Y, et al. (1993) Inhibition of histamine 
secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-
2H3 cells. J Biol Chem 268: 25846-25856. 
39. Gharbi SI, Zvelebil MJ, Shuttleworth SJ, Hancox T, Saghir N, et al. (2007) Exploring the 
specificity of the PI3K family inhibitor LY294002. Biochemical Journal 404: 15-21. 
40. Scherle PA, Ma WG, Lim H, Dey SK, Trzaskos JM (2000) Regulation of cyclooxygenase-2 
induction in the mouse uterus during decidualization - An event of early pregnancy. 
Journal of Biological Chemistry 275: 37086-37092. 
41. Faber AC, Li D, Song Y, Liang MC, Yeap BY, et al. (2009) Differential induction of apoptosis 
in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A 
106: 19503-19508. 
42. Grosa G, Allegrone G, Del Grosso E (2005) LC-ESI-MS/MS characterization of 
strophanthin-K. J Pharm Biomed Anal 38: 79-86. 
43. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, et al. (2009) An inhibitor of 
NEDD8-activating enzyme as a new approach to treat cancer. Nature 458: 732-736. 
44. Choi BH, Kim W, Wang QC, Kim DC, Tan SN, et al. (2008) Kinetin riboside preferentially 
induces apoptosis by modulating Bcl-2 family proteins and caspase-3 in cancer cells. 
Cancer Lett 261: 37-45. 
45. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, et al. (2008) Identification of kinetin 
riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J 
Clin Invest 118: 1750-1764. 
46. Vasquez RJ, Howell B, Yvon AM, Wadsworth P, Cassimeris L (1997) Nanomolar 
concentrations of nocodazole alter microtubule dynamic instability in vivo and in vitro. 
Mol Biol Cell 8: 973-985. 
47. Burns CJ, Fantino E, Phillips ID, Su S, Harte MF, et al. (2009) CYT997: a novel orally active 
tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in 
vitro and in vivo. Mol Cancer Ther 8: 3036-3045. 
48. Hasler CM, Acs G, Blumberg PM (1992) Specific binding to protein kinase C by ingenol and 
its induction of biological responses. Cancer Res 52: 202-208. 
49. Harbinski F, Craig VJ, Sanghavi S, Jeffery D, Liu L, et al. (2012) Rescue screens with 
secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving 
cancer growth. Cancer Discov 2: 948-959. 
50. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, et al. (2012) Widespread potential for 
growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487: 505-509. 
83 
 
51. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, et al. (2007) Coactivation 
of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. 
Science 318: 287-290. 
52. Sos ML, Michel K, Zander T, Weiss J, Frommolt P, et al. (2009) Predicting drug 
susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest 119: 
1727-1740. 
53. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, et al. COT drives 
resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468: 968-
972. 
54. Peck D, Crawford ED, Ross KN, Stegmaier K, Golub TR, et al. (2006) A method for high-
throughput gene expression signature analysis. Genome Biol 7: R61. 
55. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set 
enrichment analysis: a knowledge-based approach for interpreting genome-wide 
expression profiles. Proc Natl Acad Sci U S A 102: 15545-15550. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
A Genome-Scale shRNA Screen for Mediators of EGFR-Inhibitor Response 
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ABSTRACT 
 
 Activating mutations in the epidermal growth factor receptor (EGFR) gene are the major 
genetic determinant underlying clinical response of non-small cell lung cancers (NSCLCs) to the 
EGFR-tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib. Despite the marked efficacy of 
EGFR-targeted therapies in NSCLC patients harboring these mutations, however, the 
development of acquired drug resistance in these patients limits the ability of EGFR-TKIs to 
serve as a long-term treatment strategy. We have sought to uncover mediators of EGFR-TKI 
response, and loss-of-function mechanisms of drug resistance, using an RNA interference 
screening approach, potentially providing insight into new therapeutic opportunities to overcome 
acquired resistance. Using this approach, we have identified numerous candidate genes for 
further investigation and present intersecting findings with gene-expression-based studies of 
EGFR-TKI resistance. 
 
INTRODUCTION  
 The epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) gefitinib 
and erlotinib are effective therapies for non-small cell lung cancers (NSCLCs) harboring 
activating mutations in EGFR [1,2,3,4,5,6,7,8,9], but all patients eventually develop resistance to 
therapy [10]. While mutations in EGFR provide a genetic determinant of sensitivity to EGFR-
TKIs, this sensitivity cannot be invoked simply by expressing mutant EGFR in transfected cells 
[11]. Rather, EGFR ‘oncogene addiction’ seems to imply that dependence on the EGFR 
pathway relies on not only these mutations but the presence of a unique cellular context-- one 
that may potentially be exploited therapeutically in addition to targeting the receptor itself. We 
have sought to identify genes that mediate EGFR-TKI sensitivity and thus cooperate to maintain 
the ‘oncogene-addicted’ state in EGFR-mutant cells, potentially providing insight into alternative 
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‘druggable’ targets that could be used to develop long-term treatment strategies and overcome 
acquired resistance. 
 To this end, we have screened for genetic mediators of drug sensitivity in an EGFR-
mutant cell line using an unbiased pooled RNAi screening approach. Genome-wide multiplex 
shRNA screening strategies aim to systematically interrogate gene function in a given biological 
system in an unbiased fashion. This approach involves infecting cultured cells with a pool of 
shRNAs, allowing the cells to proliferate for a period of time, selecting cells displaying a desired 
phenotype (often, survival), isolating the shRNA sequences from the selected cells by PCR 
amplification, and measuring the relative abundance of the shRNAs using either a microarray or 
next-generation sequencing [12,13,14,15]. This study describes a genome-wide RNAi approach 
to interrogate sensitivity to the EGFR-TKI erlotinib. Using this approach, we have identified 
numerous candidate genes for further investigation, a subset of which intersect with gene-
expression-based studies of EGFR dependence. 
 
RESULTS 
A genome-scale pooled shRNA-based screen for mediators of erlotinib sensitivity 
 We have performed a genome-scale, multiplex shRNA screen to interrogate sensitivity 
to the EGFR tyrosine kinase inhibitor erlotinib. EGFR-mutant, erlotinib-sensitive PC9 NSCLC 
cells were infected with a genome-scale lentiviral pool of shRNAs (~90K unique shRNAs 
targeting approximately 17,000 genes; RNAi platform, Broad Institute) at an MOI of 0.3, and 
following selection for infected cells, treated with 70 nM or 250 nM erlotinib (corresponding to 
~97% and ~99% cell killing over the course of the screen, respectively) or DMSO. Cells were 
subsequently cultured for approximately 1-2 weeks, and surviving (i.e. drug-resistant) cells at 
two time points were harvested and subjected to downstream DNA processing and shRNA 
deconvolution by next-generation sequencing (Figure 3-1).  
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Figure 3-1. Loss-of-function pooled shRNA screening approach. Pooled shRNA screening 
workflow. EGFR-mutant, erlotinib sensitive PC9 cells were infected with a pooled shRNA library 
of approximately 90K shRNAs. Following selection for infected cells, cells were treated with 70 
nM or 250 nM erlotinib (suppressor treatment arm) or DMSO (reference treatment arm). 
Surviving cells were harvested after 9 and 16 days of DMSO/drug treatment and processed for 
shRNA deconvolution using next-generation sequencing (Illumina). Figure adapted from [12]. 
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 In seeking to distinguish shRNAs reflecting biological ‘hits’ from those corresponding to 
background signal—a task potentially confounded by the presence of multiple screening  
conditions and the absence of a known positive control-- we have devised a new analytical 
approach to identify candidate erlotinib-sensitizing genes that allows us to integrate data 
generated from all screening conditions, without reliance on calibration to known reference 
genes or inference of on/off-target hairpin performance. This approach is based on 1) the 
observation, made by comparing the distributions of sequencing reads across the six screening 
conditions (early and late time points for each of three treatment conditions: DMSO, 70 nM 
erlotinib, and 250 nM erlotinib), that the proportion of depleted hairpins escalates coordinately 
with drug dose and time (Figure 3-2A), and 2) the premise that shRNAs conferring drug 
resistance will become successively enriched in a population as increasingly stringent selective 
conditions are imposed. 
 In this way, we identified shRNAs whose relative abundance increases monotonically as 
a function of selective pressure. The analysis displayed in Figure 3-2A suggested that screening 
conditions could be ordered by their increasing degree of stringency as follows: DMSO early, 
DMSO late, 70 nM erlotinib early, 70 nM erlotinib late, 250 nM erlotinib early, and finally, 250 nM 
erlotinib late. We next identified ~7000 shRNAs that were enriched relative to DMSO under the 
most stringent condition, late time point, 250 nM erlotinib-treatment (Figure 3-2B, left). These 
enriched shRNAs were then clustered by their relative abundance to DMSO across all 
screening conditions, with screening conditions plotted in increasing order of stringency (Figure 
3-2C). Three of eight clusters were found to display the expected pattern of shRNA enrichment 
with increasing drug dose and treatment duration (Figure 3-2C, red boxes; Figure 3-2B, right). 
To further filter out off-target effects, candidate erlotinib-sensitizers were designated as genes 
that had at least two shRNAs represented among these three cluster groups. These resultant 
566 genes (listed in Table 3-1) were carried forward for functional validation.  
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Figure 3-2. Analytical methods used to detect shRNAs enriched with drug treatment. (A) 
The proportion of depleted shRNAs increases with drug dose and time. shRNAs across six 
screening conditions, along with the starting 90K plasmid pool, are binned according to their 
corresponding number of (log2-normalized) sequencing reads. (B) Volcano plots illustrating p-
value vs. fold- change of the 250 nM late condition relative to DMSO. Left, all points with a 
positive fold-change were subjected to the clustering analysis in (C). Right, points in red 
represent shRNAs belonging to clusters 1, 3, and 5 described in (C). (C) ~7000 shRNAs found 
to be enriched over DMSO in late time point, 250 nM drug-treated samples (see (B), left panel) 
were clustered by their relative abundance to DMSO across all screening conditions, plotted in 
increasing order of stringency. Clusters 1, 3, and 5 (red boxes) were selected as those 
exhibiting the expected pattern of enrichment. 
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Figure 3-2 (Continued) 
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Figure 3-2 (Continued) 
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Table 3-1. Candidate erlotinib-sensitizing genes. 566 genes with 2 or more shRNAs 
represented among clusters 1, 3, and 5 in Figure 3-2C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
ABCF1 BCR CDK9 DHCR24 GBAS ITGB1BP1 MBTPS2 NOP10 POLR3K RFC5 SFPQ TES UCHL1
ABHD15 BICC1 CDR2L DKC1 GCC1 ITM2B MCEE NPR1 POLRMT RFNG SH2D4A TFIP11 UFSP2
ABHD3 BMPR1B CEP120 DNAJB12 GCLC ITPK1 MCM3AP NR2F2 PPA2 RGS5 SH3BGRL3 TGFB1 UHMK1
ABHD5 BNC2 CFL1 DOK4 GLMN ITPR3 MDK NR5A2 PPFIBP1 RIOK3 SHCBP1 THOC3 ULK1
ABHD6 BOLA3 CHD4 DUS4L GLRX2 JTB MEMO1 NRBP1 PPP1CA RIPK1 SIRPA THRA UNC13B
ABL1 BRCA2 CHEK2 DYNC2LI1 GLUD1 JTV1 MEST NSBP1 PPP1CC RNF6 SLC25A36 THUMPD1 UQCRB
ACAD8 BRD4 CHMP4C E2F1 GNAQ KCNN4 METTL11A NSF PPP1R11 ROCK2 SLC38A10 TIMM8B USP1
ACCN2 BRMS1 CHMP7 EBP GNS KDELR2 METTL13 NUBP1 PPP2CB RP11‐217H1.1 SLC7A5 TKT USP12
ACO1 BSG CHN1 ECD GOLGA7 KIAA0528 MFSD8 NUP205 PPP2R2C RPL36AL SLFN5 TM7SF3 USP25
ACSS3 BUD31 CIB1 EEF1A1 GOLPH3 KIAA0831 MGRN1 NXPH4 PPP3R1 RPL37 SMARCD1 TMBIM6 USP30
ACTB C15orf24 CKAP2 EGLN2 GRPEL1 KIAA1303 MGST2 OAS1 PRICKLE1 RPL39 SMARCD2 TMEM120A USP33
ACTR3 C16orf53 CLDND1 EIF2S1 GSTO1 KIAA1804 MIB1 OBFC2B PRKAR2B RPL39L SMC5 TMEM14A USP7
ADAR C16orf62 CLIC1 EIF5A GTF2F1 KIDINS220 MIF4GD ODC1 PRKD2 RPL8 SNAP25 TMEM214 UTP11L
ADC C17orf81 CLPP EIF5B GTF2H3 KIF3C MKNK2 OLFML2A PRKD3 RPLP1 SNF1LK2 TMEM30A VAPB
ADCK1 C19orf56 CLTC ELAC2 GTPBP8 KRCC1 MLF2 OSBPL10 PROS1 RPP40 SNX11 TMEM38B VHL
AFTPH C1orf174 CMPK EMG1 GUSB KRT10 MLPH OSBPL9 PRPS1L1 RPRD1B SNX3 TMEM45A VRK2
AIP C21orf6 CMTM6 EPHA7 H1FX L3MBTL MLX P4HA2 PRPS2 RPS6KC1 SNX6 TMEM47 WASF3
AK1 C4orf27 COASY ERCC1 HBS1L LAMB1 MMAB PAF1 PSEN1 RRM2B SOD1 TMEM50B WBP2
AK7 C6orf108 COBRA1 ERCC8 HD LAMC1 MOSPD1 PAK1 PSMA4 RRP12 SOX9 TMEM70 WDR13
ALCAM C9orf46 COG7 ESF1 HDAC11 LARP6 MOSPD2 PAPD4 PSMA6 RRP1B SPAG5 TMEM85 WDR45
ALDH7A1 C9orf6 CORO2A ESRRA HDAC2 LARP7 MPP5 PAQR5 PSMA7 RSRC2 SPHK1 TNKS WDR8
ALG8 C9orf80 COX4NB ETV6 HEATR1 LBR MRCL3 PARVB PSMB8 SAMHD1 SPOP TOMM34 XRCC6
AMD1 CA9 CPNE2 EXO1 HINT2 LEO1 MRLC2 PAWR PSMC3IP SAP130 SPR TOMM7 XRN2
AMOT CALM2 CPSF1 F2R HN1 LEPREL4 MRPL22 PCCB PSMC5 SARS SRP14 TOX4 ZAK
ANKRD11 CALM3 CPSF3L FAM136A HNRPH2 LHPP MRPL32 PCTK1 PSMD1 SAT2 SRPR TP53 ZBTB8OS
ANXA10 CALR CRABP2 FAM162A HRB LPCAT4 MRPS22 PDCD6IP PSMD6 SBF1 STAG2 TPD52L3 ZC3H14
AP1S2 CALU CSGALNACT2 FAM172A HSCB LPIN2 MRPS31 PDIA3 PSMF1 SCAMP1 STAT3 TRIM16 ZCCHC10
AP2M1 CAMK1D CSK FAM175B HSPA9B LRBA MSH2 PDK1 PSTPIP2 SCAP2 STK24 TRIM24 ZFAND1
APEX1 CAND1 CSNK1A1 FAM48A HSPB1 LSM7 MTFR1 PEX11B PTCD1 SCARB2 STK32B TRIM36 ZFR
ARFIP1 CAPG CSNK1G2 FAM50A HSPB8 LTB4DH MTHFD1 PEX3 PTDSS1 SCCPDH STK32C TSC22D1 ZHX3
ARHGAP18 CASK CTSL FAM65A IDH1 LUM MYLK PFKFB1 PTGES SCPEP1 STOM TSPAN14 ZMYM4
ARL2BP CASP9 CUL2 FASTKD2 IFI35 MAGI3 NACA PFKFB2 PTK2 SCRN1 STUB1 TSPAN6 ZNF263
ARMC8 CCDC104 CUL4B FAU IFT81 MANEA NARS PFKL PTTG1 SCYL1 STX12 TSPYL1 ZNF426
ARPC1B CCDC91 CYB5B FBXO17 IHPK1 MAP1B NCKAP1 PGK1 PXMP4 SDCCAG10 STX18 TTC35 ZNF45
ARPC3 CCDC92 CYBA FBXO5 IKBKB MAP2K2 NDUFAF4 PHACTR2 RAB11FIP1 SEC14L4 SUB1 TTK ZNF767
ATOH8 CCND3 CYCS FEZ2 ILF2 MAP3K11 NDUFB7 PHB RAB25 SEC61A1 SUCLG1 TUBA6 ZNHIT1
ATP2B1 CCT3 CYP51A1 FGL1 ILF3 MAP3K6 NDUFS4 PHKA1 RAD23B SEC61A2 SULT2B1 TUBB2C ZW10
ATP5G2 CCT4 DCAF6 FKBP10 INTS3 MAPK1 NEDD8 PIGV RAD51 SEC61B TAF11 TXNDC5 ZWINT
ATP6V0C CCT6B DCAF7 FKBP1B IP6K1 MAPK15 NFU1 PLCB3 RAE1 SECTM1 TARBP2 UAP1
ATP6V0D1 CDC2L5 DDX23 FKBP3 IPO7 MAPK1IP1L NLK PLEKHA1 RANGAP1 SELT TARS UBB
AUP1 CDC42BPB DDX46 FLII IPP MAPK8 NMD3 PLEKHM1 RBMX2 SEPT7 TBC1D1 UBC
BCKDHA CDIPT DECR1 FLJ25476 IRAK1 MARK4 NME2 PLK1 RCAN3 SEPW1 TCEB3 UBE2Q1
BCKDK CDK5 DENR FOSL2 ITFG1 MAST2 NME7 POLD1 RER1 SERINC1 TCP1 UBE3B
BCL3 CDK5RAP3 DGKE GAK ITGAV MBD4 NOL8 POLR2I REXO2 SETD4 TCTN3 UBE3C
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Functional validation approaches of candidate erlotinib-sensitizing genes  
 
 The 566 genes described above were first used to perform a pathway analysis (Figure 3-
3) (IPA, Ingenuity Systems) to identify biological functions that are significantly associated with 
candidate-erlotinib sensitizing genes. The most strongly-associated biological function was post-
translational modification, followed by molecular transport, protein trafficking, and cell death. 
 We pursued a two-pronged approach to validate candidate erlotinib-sensitizing genes. 
The first approach was to perform low-throughput validation of a small and biased set of genes. 
Experimental approaches included assaying target gene expression using immunoblotting and 
quantitative PCR (qPCR), and measuring changes in drug sensitivity induced by these shRNAs 
using standard multipoint growth inhibition assays. The second approach was to pursue high-
throughput and unbiased validation of all 566 candidate erlotinib-sensitizing genes. In this case, 
the experimental approach was to perform secondary screens using a targeted ‘minipool’ of ‘hit’ 
shRNAs and controls in additional EGFR-mutant, erlotinib-sensitive cell lines. Given the large 
set of ‘hit’ genes, secondary screens using a targeted minipool, which may be more readily 
scaled to test a large number of genes across multiple cell lines and conditions, were favored to 
an arrayed format.  
 Six ‘hit’ genes of particular biological interest were chosen for low-throughput validation 
(RAD51, MBD4, ZBTB8OS, IDH1, PTTG1, and BMPR1B). Each of these genes had at least 3 
shRNAs enriched over DMSO in the primary screen. To assess the on-target effects of these 
genes’ corresponding shRNAs in the primary screen, we compared the enrichment of these 
shRNAs in the primary screen with their ability confer gene knockdown, as measured by high-
throughput qPCR data (previously generated to assess library performance by the RNAi 
Consortium, Broad Institute) (Figure 3-4). This analysis suggested a strong relationship between 
shRNAs that scored most significantly in the primary screen (as assessed by p-value; see 
Figure 3-2B, left) and the degree of target knockdown (Figure 3-4), suggesting that greater 
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Figure 3-3. Biological functions associated with candidate erlotinib-sensitizing genes. 
566 candidate erlotinib-sensitizing genes were used to perform IPA pathway analysis (Ingenuity 
Systems) to identify significantly associated biological functions. 
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Figure 3-4. On-target effects of candidate resistance-mediating shRNAs. Selected ‘hit’ 
genes and the screening performance of their associated shRNAs versus degree of target 
knockdown. Enrichment in the primary screen is measured by a given shRNA’s p-value (see 
Figure 3-2B, left), and percent gene expression is measured by high-throughput qPCR. Black 
points denote shRNAs that are enriched relative to DMSO, and red points denote shRNAs that 
are depleted relative to DMSO. Clustering of black points near the origin suggests on-target 
shRNA effects. PTEN and EGFR genes are listed for reference. 
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knockdown is associated with more significant enrichment under erlotinib treatment. 
 To test whether shRNAs that are highly enriched in the primary screen and appear to be 
on-target can induce erlotinib resistance in validation assays, we performed multipoint drug 
sensitivity assays on PC9 cells expressing candidate resistance-mediating shRNAs. shRNAs 
were chosen based on enrichment in the primary screen (based on p-value) as well as evidence 
of knockdown as measured by high-throughput qPCR data. In several cases, knockdown was 
also confirmed by Western blot (data not shown). PC9 cells were transduced with two shRNAs 
for each of the six genes listed above, and cells stably expressing these shRNAs were 
subjected to 72-hour drug-sensitivity assays (Figure 3-5). While these ‘hit’ shRNAs were 
expected to shift drug sensitivity curves in a manner consistent with drug resistance, no 
appreciable shift was observed (Figure 3-5) relative to cells transduced with shRFP. 
 It is unclear what is underlying the discrepancy between the findings of Figure 3-4 and 
Figure 3-5.  The inability of these selected genes to validate the primary screening results, 
despite exhibiting patterns of knockdown-dependent enrichment in the primary screen, suggests 
that knockdown of these genes may have provided some fitness advantage unrelated to EGFR-
inhibitor resistance.  These data also suggest that bona fide resistance-mediating shRNAs may 
represent a smaller fraction of candidate shRNAs than initially expected. 
 Thus, high-throughput validation approaches are being pursued using a targeted 
minipool of hit shRNAs (described in Materials and Methods). Next steps will be to screen 
additional cell lines using multiple drug doses and a longer time course than that of the primary 
screen, to elicit a higher level of selection. To avoid selection of potentially preexisting 
gatekeeper mutation-positive subpopulations during the course of this longer follow-up screen, 
single cell clones of the original screening cell line (PC9) were isolated and confirmed to be WT 
at the gatekeeper residue (T790) as well as positive for the primary EGFR mutation.  
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Figure 3-5. Selected candidate resistance-mediating shRNAs do not confer erlotinib 
resistance in validation assays. PC9 cells transduced with selected candidate resistance-
mediating shRNAs were treated with increasing doses of erlotinib and assayed for cell viability 
after 72h using the WST-1 reagent. Data are expressed as percent viability relative to vehicle-
treated cells and represent the mean ± SD of 5 replicates. Graphs with identical control curves 
reflect experiments performed in parallel on the same day. 
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Intersection of screening findings with gene-expression-based studies of EGFR-TKI 
sensitivity 
 We have previously described a gene-expression-based strategy for identifying genetic 
and chemical perturbations that can induce or reverse EGFR-TKI resistance (Chapter 2). This 
approach entailed using an expression-profiling resource created by the Library of Integrated 
Network-based Cellular Signatures (LINCS) program (lincscloud.org) to identify genes and 
compounds whose transcriptional effects mimic those of erlotinib-resistance-mediating open 
reading frames (ORFs) (Chapter 2). As the LINCS database contains gene-expression profiles 
generated from human cells treated with shRNA reagents, we asked if an analogous query of 
LINCS shRNAs would yield target genes that intersect with our pooled screen findings. 
 Gene-expression signatures from cells expressing resistance-mediating genes were 
independently used to query LINCS, as described in Chapter 2. In this case, we looked for 
shRNA perturbations whose transcriptional effects were correlated with those of resistance-
inducing genes. We hypothesized that, on the basis of their shared transcriptional effects, such 
shRNAs could potentially also induce erlotinib resistance and thus may overlap with pooled 
shRNA findings. We observed that, among the LINCS shRNA target genes that most positively-
correlate with resistance-mediating ORFs (the top 5% of all shRNA target genes), 14 genes 
intersect with pooled screen candidates (Figure 3-6). We noted that one of these genes, CSK or 
C-Src kinase, is a known negative regulator of the Src-family of kinases [16,17] and thus is 
consistent with previous work implicating the Src-family of kinases in EGFR-inhibitor resistance 
(Chapter 1). On the basis of their identification using orthogonal approaches, these 14 genes 
warrant further study for their ability to mediate response to EGFR inhibition. 
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Figure 3-6. Intersection of candidate erlotinib-sensitizing genes nominated by pooled 
RNAi screening and LINCS analysis. The LINCS database was queried to identify shRNA 
target genes whose transcriptional effects correlate with those of resistance-inducing ORFs. 
The candidate erlotinib-sensitizing genes that are common to both the LINCS analysis and the 
pooled RNAi screening approach are listed. 
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DISCUSSION 
 In this study, we have aimed to screen for mediators of EGFR-TKI sensitivity, and loss-
of-function mediators of EGFR-TKI resistance, in an EGFR-dependent model. While EGFR-TKI 
resistance is commonly attributable to gain-of-function alterations, such as amplification of the 
receptor tyrosine kinase MET [18], loss-of-function events have also been implicated in reduced 
EGFR-TKI sensitivity. Examples include loss of the phosphatase and tensin homolog (PTEN) 
gene, and lower expression of the pro-apoptotic BCL2 family member BIM, which are both 
associated with reduced response to EGFR-TKIs [19,20]. These observations suggest that 
certain genes mediate EGFR-TKI response, and thus lead to drug resistance when lost or 
downregulated. Here, we report a genome-scale shRNA-based screen to identify genes whose 
suppression can confer resistance to EGFR inhibition, thus representing mediators of erlotinib 
sensitivity in EGFR-dependent cells. 
 This approach yielded a large number of candidate erlotinib-sensitizing genes, though 
preliminary validation data (Figure 3-5 and data not shown) suggest that many of these genes 
are likely not erlotinib-sensitizing. Current efforts include a more systematic and unbiased 
validation approach using a targeted minipool of candidate resistance-mediating shRNAs. 
Intersection of screening findings with a LINCS-based query, however, has identified 14 genes 
that display evidence of being erlotinib-sensitizing using two independent approaches. 
Collectively, these data identify a large number of candidate erlotinib-sensitizing genes, and 
nominate a subset of genes for further investigation. 
  
MATERIALS AND METHODS 
 
Cell culture and reagents 
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 The EGFR-mutant NSCLC cell line PC9 (del E746_A750) has been described previously 
[21]. Cells were maintained in RPMI (Cellgro) supplemented with 10% FBS (Gemini 
Bioproducts). Erlotinib was purchased from LC Laboratories. 
 
Pooled shRNA screen 
 Screening was performed using a genome-scale library of 89,771 shRNAs (Broad 
Institute pooled 90K shRNA library). PC9 cells were incubated with lentivirus corresponding to 
the 90K pooled shRNA library in the presence of 4 µg/mL polybrene, dispensed in 12-well plates 
(24 plates with 3 x 106 cells per well), and spin-infected at 2000 rpm for 2h at 30°C. Lentivirus 
was titered to achieve a MOI of approximately 0.3. After spin-infection, virus-containing media 
was replaced with standard growth media, and cells were incubated at 37°C overnight. The 
following day, cells were trypsinized and pooled, then expanded for 4 days in selective media 
containing 2 µg/mL puromycin. Five days after infection, cells were divided across drug-treated 
(approximately 100 x 106 cells for each of 12 replicates) and DMSO-treated (30 x 106 cells for 
each of 3 DMSO replicates) arms; cells were treated with DMSO (3 replicates), 70 nM erlotinib 
(6 replicates), or 250 nM erlotinib (6 replicates), in 2 µg/mL puromycin-containing media. Media 
containing DMSO or erlotinib, plus 2 µg/mL puromycin, was replenished every three days, and 
cells were re-plated as needed until cell harvests at two timepoints. After 9 days of drug/DMSO 
treatment (early timepoint), all cells were collected for three replicates each of the two drug-
treated arms, and >30 x 106 cells were harvested for each of the three DMSO replicates. After 
16 days of drug/DMSO treatment (late timepoint), all cells were collected for the remaining drug-
treated replicates (3 replicates per dose), and 80 x 106 cells were harvested for each of the 
three DMSO replicates. Cells were stored at -20°C in PBS until genomic DNA isolation steps. 
 
shRNA deconvolution by Illumina sequencing 
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 Genomic DNA was purified from harvested cells (all 12 drug-treated replicates and 1 
DMSO replicate from each timepoint) using the QIAamp DNA Blood Kit (Qiagen), and shRNA 
regions were amplified from purified genomic DNA using a nested PCR reaction. Conditions for 
the first round of amplification have been described previously [22]. Here, up to 6 µg of genomic 
DNA was used for each PCR reaction, and up to 29 parallel PCR reactions were performed for 
each sample. Thermal cycler conditions for the first round of amplification were 95°C for 5 min; 
18 cycles of 94°C for 30 sec, 65°C for 30 sec, 72°C for 20 sec; and 72°C for 10 min. Parallel 
PCR reactions for a given sample were pooled, then used to perform a second amplification 
round. Conditions for the second round of amplification were adapted from [22]. Thermal cycler 
conditions for the second round of amplification were 95°C for 1 min; 18 cycles of 94°C for 30 
sec, 58°C for 30 sec, 72°C for 20 sec; and 72°C for 10 min. PCR-amplified DNA was pooled 
and processed for massively parallel sequencing (Illumina) as described previously [22]. 
 Genomic DNA for each sample was also used to sequence EGFR for the presence of 
the resistance-associated T790M gatekeeper mutation [23,24] by Sanger sequencing. All 
samples were wild-type at position 790 (data not shown). 
 
Identification of candidate resistance-mediating shRNAs 
 Sequencing reads were log2-normalized as described previously [15]. A t-test was 
performed between 250 nM erlotinib-treated, late time point replicates and DMSO-treated 
replicates (early and late time points), and all shRNAs with a positive fold-change over DMSO 
were used for subsequent analyses. For each treatment condition, shRNA abundance was 
normalized to DMSO then subjected to clustering using Mfuzz soft clustering software [25]. 
Genes with 2 or more shRNAs represented among clusters 1, 3, or 5 (see Figure 3-2C) were 
designated as candidate erlotinib-sensitizing genes (listed in Table 3-1). 
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Quantitative real-time PCR 
 High-throughput quantitative real-time PCR data was previously generated by the Broad 
Institute’s RNAi Platform. 
 
Plasmids 
 The shRNA constructs used targeted: BMPR1B (TRCN0000197141 and 
TRCN0000199481); MBD4 (TRCN0000013313 and TRCN0000013314); IDH1 
(TRCN0000220373 and TRCN0000220377); PTTG1 (TRCN0000015105 and 
TRCN0000015106); ZBTB8OS (TRCN0000131054 and TRCN0000130822); and RAD51 
(TRCN0000018876 and TRCN0000018879).   
 
Virus production  
 Lentivirus was produced by transfection of 293T packaging cells with plasmids 
corresponding to pLX-Blast-V5-ORF, Δ8.9 (gag, pol), and VSV-G; and FuGene6 transfection 
reagent (Roche) as described previously [26].  
 
Drug sensitivity assays 
 PC9 cells stably expressing candidate resistance-mediating shRNAs were seeded 
overnight in 96-well plates at a density of 4000 cells per well. The following day, were treated 
with erlotinib or DMSO (1:1,000 dilution). Erlotinib was tested at each of the following 
concentrations: 100, 10, 1, 0.3, 0.1, 0.01, 0.001, 0.0001 and 0.00001 µM. Cell viability was 
assayed 3d after the addition of erlotinib or DMSO using WST-1Reagent (Roche). Drug-treated 
cells were normalized to DMSO-treated cells to calculate relative percent viability. Relative 
percent viability values and dose-response curves were plotted using GraphPad Prism software 
(GraphPad). 
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LINCS shRNA analysis 
 
 Gene-expression profiling and signature generation methods for resistance-mediating 
ORFs have been described previously (Chapter 2, Materials and Methods). Signatures from 
each of the 12 positive-phenotype genes (Chapter 2) were used to independently query 
consensus gene signatures (CGS) derived from multiple shRNAs in the LINCS dataset. Each 
CGS–ORF query pair was assigned a connectivity score [27] computed using the weighted 
Kolmogorov-Smirnov statistic [28]. All CGSs in the dataset were rank-ordered by their 
connectivity scores to a given ORF query. To identify CGSs that were consistently correlated to 
the query ORFs, we computed every CGS’ median normalized rank across all 12 ORFs.  
 
Curation of targeted minipool 
 A targeted minipool of candidate erlotinib-sensitizing genes was curated as follows. In an 
attempt to include biologically relevant shRNAs for each ‘hit’ gene while limiting the overall size 
of the minipool, three shRNAs targeting each of the 566 genes described above were manually 
curated based on two independent metrics: performance in the primary screen (shRNAs with 
most the significant q-value), and degree of knockdown as measured by high-throughput qPCR 
data (previously generated to assess library performance by the RNAi Consortium, Broad 
Institute). For controls, standard inert shRNAs (e.g. targeting GFP, RFP, luciferase); shRNAs 
targeting potentially biologically relevant genes (e.g. EGFR, PTEN); and an additional ~100 
shRNAs that were deemed the most inert in DMSO early/late samples in the primary screen 
(but depleted with drug-treatment) were included. These ~100 shRNAs were included to help 
define the distribution of background signal. 
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 The phenomenon of ‘oncogene addiction’ has contributed to several paradigm shifts in 
the characterization and management of cancer. The understanding that a tumor cell can exhibit 
exquisite dependence on a single protein despite the accumulation of multiple genetic 
alterations has had important implications with respect to the diagnosis and classification of 
tumors, the patient selection criteria for a specific therapy, the types of therapeutic agents now 
used to treat cancers, and the way resistance to therapy develops and is treated. Drug 
resistance in particular is closely intertwined with the phenomenon of oncogene dependence, as 
the ‘addicted state’ presumably necessitates either retained activity of the primary oncogene in 
the presence of drug, or, in the face of successful oncogene inactivation, the enlistment of other 
genes with redundant functional effects. In this way, addiction and resistance represent two 
faces of a common coin in oncogene-driven cancers, related by their shared ability to sustain a 
specific cellular state.                                                                                                                 
 The advent of large-scale functional screening libraries to perturb mammalian models 
has enabled unbiased and comprehensive interrogation of oncogene dependence and drug 
resistance. It is now possible to identify the full-range of genes that can enhance or suppress 
dependence on a given oncogene, using both gain- and loss-of-function approaches. 
Interrogating a wide-range of genes is useful not only in terms of broadening the scope of these 
studies, but because this may permit investigators to identify crucial commonalities among 
genes sharing a particular phenotype. This may be particularly relevant in the case of drug 
resistance, where the sufficiency to induce resistance in in vitro models does not necessarily 
translate to an endogenous resistance mechanism in the in vivo setting. Yet understanding 
shared features among various in vitro resistance mechanisms, even if many are not clinically 
relevant, may elucidate signaling effectors critical to oncogene bypass.     
 In our gain-of-function studies of EGFR-inhibitor resistance, for example, we identified a 
broad spectrum of kinase genes that could bypass dependence on EGFR (Figure C-1). In some 
respects, the kinases that were identified using this approach were relatively diverse: they  
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Figure C-1. Utilizing large-scale functional screening approaches to identify shared 
effectors of oncogene bypass. (A) EGFR-mutant cancers are singularly dependent on the 
EGFR signaling input (bold arrow) for activation of downstream signaling pathways, at the 
expense of other signaling inputs (gray arrows). These tumors are thus highly susceptible to 
EGFR inhibition with an EGFR inhibitor. (B) In Chapter 1, we identified a broad range of kinase 
genes with the ability to drive EGFR-dependent cells in the setting of EGFR inhibition. 
Identifying a spectrum of kinase genes with this function facilitated the unbiased identification of 
signaling effectors commonly required for EGFR bypass. A portion of this figure is reprinted 
from [1]. 
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included several tyrosine kinase subfamilies of both receptor and non-receptor kinase classes, 
as well as serine/threonine kinases. Yet we determined that many of these resistance-mediating 
genes were remarkably similar with respect to the transcriptional changes they could effect. It 
was on the basis of their shared gene-expression signatures that we could, in an unbiased 
fashion, implicate the PI3K-AKT and MEK-ERK pathways as the critical and shared mediators 
of EGFR bypass for these genes (Figure C-1). One might imagine other scenarios in which 
several subclasses of resistance mechanisms could be defined using such an approach.  
 These studies also underscore the combined power of gene-expression profiling, the 
LINCS gene-expression resource, and pattern-matching software to identify functional 
relationships between genetic and chemical perturbations. Our gene-expression-based studies 
in Chapter 2 illustrate that a cell’s gene-expression state can faithfully reflect its phenotypic 
behavior with respect to drug response and resistance. Remarkably, these gene-expression 
states were also highly context-independent. With this analysis, we were able to identify 
compounds that could reverse EGFR-inhibitor resistance and as well as compounds that could 
reduce EGFR-inhibitor sensitivity. We were also able to integrate findings from our ORF- and 
shRNA-based screens based on their shared transcriptional profiles. The genetic and chemical 
modifiers of EGFR dependence that were identified using these functional genetic and 
integrative approaches are summarized in Figure C-2.    
 Several questions emerge from these studies. For example, given the broad spectrum of 
kinases sufficient to drive EGFR-TKI-resistance, it is unclear why there appears to be 
preferential activation of specific bypass genes, such as MET, in the clinical setting. One 
possible explanation is that genes like MET provide additional fitness advantages or are more 
readily altered. Related to this, our finding that copy number gains of FGR and LCK frequently 
co-occur with EGFR alterations raises the question of if and how these alterations may influence 
EGFR dependence in the clinical setting. The ultimate goal of these studies remains how to 
better understand resistance as it relates to patients with cancer.  
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Figure C-2. Genetic and chemical modifiers of EGFR dependence in non-small cell lung 
cancer. Summary of genes whose overexpression can reduce EGFR dependence (left column); 
chemical compounds that can reverse ORF-mediated resistance or reduce EGFR-inhibitor 
sensitivity (middle column); and candidate genes whose knockdown can reduce EGFR 
dependence (right column).  Newly-described resistance-mediating ORFs are labeled red. The 
chemical structure displayed is reprinted from [2]. 
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 In summary, we describe a methodology in which resistance-mediating genes were first 
identified via a functional genetic screening approach, then on the basis of their transcriptional 
effects, used to identify chemical compounds with the ability to reverse (or induce) resistance. 
As emerging evidence suggests that drug resistance is an inexorable outcome of kinase 
inhibitor therapy-- irrespective of cancer type, driver alteration, or drug target—similar 
experimental pipelines may permit investigators to anticipate resistance mechanisms and 
designate appropriate therapies in the preclinical, rather than post-relapse, phase. Moreover, 
while our studies focused on a drug whose target and downstream signaling effectors are well-
characterized, this approach may be particularly useful for drugs with unknown or poorly 
characterized mechanisms of action. In this way, for a given therapy, functional screening tools 
may soon permit the simultaneous identification of resistance mechanisms and the inhibitors 
that can undo them. 
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Exploiting synthetic lethality in EGFR-mutant cancers  
 EGFR-targeted therapies for the treatment of EGFR-mutant NSCLC are modeled on the 
premise that one may achieve cancer-cell selectivity (and a high therapeutic index) by exploiting 
these cancer cells’ unique addiction to the EGFR oncogene. In theory, an alternative approach 
to achieving cancer-cell selectivity could be to exploit non-oncogene addiction—that is, to inhibit 
not EGFR itself, but rather a target that is differentially required in an EGFR-mutant context 
versus a normal cellular context [1]. This principle of synthetic lethality as applied to anticancer 
therapy— referring to the situation wherein mutation of two genes, but not of either one alone, 
results in cell death— has proven to be powerful in practice, most notably in the case of PARP1 
inhibition in the context of BRCA1 or BRCA2 mutant cells [2,3,4]. The challenge one faces in 
pursuing this ‘context-driven’ approach, however, lies in identifying the synthetic lethal 
interactions, which cannot be readily predicted a priori. Unbiased, high-throughput chemical and 
genetic screening approaches have proven to be effective strategies [5], but remain labor-
intensive and costly.  
 An alternative strategy to identify candidate synthetic lethal partner(s) of mutant-EGFR is 
to identify genes that are anti-correlated with EGFR with respect to mutational status in NSCLC 
primary tumors. That is, under the premise that mutations in synthetic lethal genes are, by 
definition, never co-occurring in a viable (tumor) cell, one could use patterns of mutational 
mutual exclusivity to predict potential synthetic lethal partners. With the availability of large-scale 
and comprehensive gene resequencing data for lung adenocarcinoma [6], it is now possible to 
identify recurrent combinatorial patterns of somatic mutations in lung cancer. Multiple lung 
adenocarcinoma sequencing efforts have reported a negative correlation between mutations in 
EGFR and STK11 (the gene encoding LKB1), in addition to well-known negative correlation 
between mutations in EGFR and KRAS [6,7,8]. 
LKB1 inactivation may alternately promote and suppress apoptosis. 
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 LKB1 is a serine/threonine kinase originally identified as the causative mutation in Peutz-
Jeghers syndrome (PJS) [9,10], an inherited autosomal dominant disorder characterized by 
benign polyps of the gastrointestinal tract and a predisposition to developing certain cancers 
[11,12].  LKB1, also known as STK11 and par-4, phosphorylates several consereved targets but 
is perhaps best known as the major upstream kinase to AMP-activated protein kinase (AMPK), 
a sensor of cellular energy levels and, by way of its activation of the tumor suppressor TSC2, an 
inhibitor of mammalian target of rapamycin (mTOR) signaling [13]. 
 In addition to germline mutations in PJS, LKB1 has been found to be somatically 
inactivated in a large percentage (~30%) of sporadic non-small cell lung carcinoma (NSCLC) 
primary tumors and cell lines [14,15,16,17] and this, in combination with substantial functional 
and genetic data, has supported a role for LKB1 as a human tumor suppressor gene [18]. 
Despite this, several reports have revealed a portrait of LKB1 deficiency that is more complex, 
and include findings that LKB1-/- mouse embryonic fibroblasts are resistant to Ha-Ras-mediated 
transformation either alone or with immortalizing oncogenes [19]; LKB1 loss attenuates Wnt 
signaling in Xenopus and mouse models [20]; and that, in tumor cells with constitutively active 
Akt, LKB1 depletion reduces Akt-mediated phosphorylation and inactivation of several pro-
apoptotic protein targets, including FOXO3a [21]. Together, these studies suggest that LKB1 
may be required for the transformation or maintenance of cancer cells in specific cellular 
contexts. 
Determining whether LKB1 is required for the EGFR-driven oncogenic state, thus 
representing a synthetic lethal partner to the EGFR oncogene 
 EGFR mutations in NSCLC primary tumors exhibit a pattern of mutual exclusivity with 
mutations in LKB1 [6,22], raising the possibility that LKB1 function is required in the setting of 
oncogenic EGFR. While the function of LKB1 is classically characterized as tumor suppressive, 
recent evidence implicates LKB1 as a required factor in AKT-mediated inactivation of the 
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proapoptotic protein FOXO3a, thereby supporting a heretofore unappreciated antiapoptotic role 
for LKB1 in NSCLC [21]. While the requirement for LKB1 is claimed by Zhong et al. to exist in 
the context of aberrant AKT activation rather than that of mutant EGFR per se, these findings 
lend support to the notion that LKB1 may serve a pro-survival function specifically in the setting 
of oncogene-addicted cancers. The following set of experiments serves to test the hypothesis 
that LKB1 inactivation is synthetic lethal to EGFR-mutant cancers by testing whether LKB1 
suppression selectively reduces the viability of cell lines harboring EGFR mutations versus non-
mutant lines.  
 To assess the role of LKB1 in promoting cell survival specifically in the setting of 
oncogenic EGFR, a tetracycline/doxycycline- inducible short hairpin RNA (shRNA) lentiviral 
vector targeting LKB1 (Supplementary Figure 1) was used to infect NSCLC cells lines of two 
genotypic/phenotypic classes: cell lines that both harbor an activating EGFR mutation and 
demonstrate EGFR dependence, as demonstrated by exquisite sensitivity to EGFR inhibitors 
(PC9, HCC4006, H3255, HCC827); and as negative controls, lines that are wild-type for EGFR 
and are impervious to EGFR inhibition (H2882, H28, H1915, H661) [23]. Briefly, an inducible 
shRNA construct, generated by sequential PCR-based modification of the pLKO.1 lentiviral 
vector, pLKO-Tet-On-STK11[24,25] was used to transduce cells. Cell viability was measured by 
seeding equal numbers of stably-infected cells in the presence or absence of 20 ng/ml 
doxycycline and measuring cell number at fixed intervals over an 8-9 day time period 
(Supplementary Figure 2, left). Gene knockdown was confirmed by immunoblot analysis using 
affinity-purified antibody specific for LKB1 (Supplementary Figure 2, right). These data 
demonstrate a dramatic loss of viability in one EGFR-mutant cell line, HCC4006, and a modest 
reduction in viability in the three other EGFR-mutant cell lines. 
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Supplementary Figure 1. Generating a system for inducible STK11 (LKB1) shRNA 
expression. An inducible shRNA contruct, pLKO-Tet-On-STK11, is able to induce doxycycline-
dependent knockdown of LKB1 in three NSCLC cell lines (H28, H2882, and PC9). 
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Supplementary Figure 2. Cell viability of NSCLC cell lines expressing pLKO-Tet-On-
STK11. Left, EGFR-mutant (red titles) and EGFR-WT (black titles) NSCLC cell lines expressing 
pLKO-Tet-On-STK11 were grown in the presence or absence of 20 ng/ml doxycycline, and cell 
number was measured at fixed intervals. Data represent the mean ± SD of 3 replicates. Right, 
conditional shSTK11 induction was confirmed by Western blot. 
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 To determine whether the observed loss of viability in some EGFR-mutant, shLKB1-
expressing cells is attributable to reduced proliferative potential of EGFR-mutant cells in the 
absence of LKB1, EGFR-mutant and wild-type NSCLC lines expressing shLKB1were assayed 
to detect levels of proliferation using a BrdU incorporation assay. EGFR-mutant and wild-type 
lines expressing pLKO-Tet-On-STK11 were grown in the presence or absence of 20 ng/ml 
doxycycline for 8 days, thereby achieving conditional LKB1 knockdown, before equal numbers 
were reseeded into 96-well plates, labeled with BrdU for 4 hours, and stained according to the 
manufacturer’s protocol (Roche) (Supplementary Figure 3). Consistent with the results of 
Supplementary Figure 1, these data revealed a dramatic reduction in the proliferation of one cell 
line, HCC4006. 
 The role of LKB1 knockdown in anchorage-independent growth, and sensitivity to 
EGFR-TKIs, was also assayed (Supplementary Figure 4 and Supplementary Figure 5, 
respectively). LKB1 knockdown did not alter either of these two phenotypes. 
 Together, these data do not suggest a synthetic lethal relationship between STK11 and 
EGFR, but do identify one cell line, HCC4006, that is highly susceptible to LKB1 knockdown.  
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Supplementary Figure 3. Cell proliferation NSCLC cell lines expressing pLKO-Tet-On-
STK11. EGFR-mutant (red) and EGFR-WT (white) cell lines expressing pLKO-Tet-On-STK11 
were grown in the presence or absence of 20 ng/ml doxycycline for 8 days, labeled with BrdU 
for 4 hours, then assayed for BrdU incorporation. Data represent the mean of 8 replicates. 
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Supplementary Figure 4. LKB1 knockdown does not impair soft agar colony formation in 
EGFR-mutant cells. EGFR WT (H2882) and mutant (PC9) cells expressing pLKO-Tet-On-
STK11 were assayed for anchorage-independent growth in the presence or absence of 40 
ng/ml doxycycline. 
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Supplementary Figure 5. LKB1 knockdown does not alter sensitivity of EGFR-mutant 
cells to erlotinib. EGFR-mutant and wild-type cells expressing pLKO-Tet-On-STK11 were 
grown in the presence or absence of 20 ng/ml doxycycline for 7 days, then treated with varying 
doses of erlotinib for 72 hours. Data represent the mean of 5 replicates. 
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